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Chapter 1 
G e n e r a l  i n t r o d u c t i o n  
General Introduction 
	 9	
Preface 
 
In the assessment of the blood coagulation system, researchers have an ever-
expanding toolkit at their disposal. They (re-)design assays to investigate 
coagulation e.g. under the influence of blood flow1,2, with and without blood 
platelets3,4 in whole blood and/or in the presence of endothelial cells5. On the 
contrary, clinicians are not exactly spoiled for choice, since most of their assays 
being based on the same clotting time measurements that date back to the middle 
of the previous century. In other words, there is a need for the clinical 
implementation of more insightful blood coagulation assays and judging from the 
number of assays used in research settings there should be sufficient choice. 
 
This thesis focusses on one test in particular, the thrombin generation test, which 
was first presented by Hemker3. The test has been around for over 15 years now 
and despite its potential as a clinically relevant measurement, still has not been 
implemented in the clinic. One of the main reasons that halted further clinical 
development was the high inter-laboratory variability that has been reported over 
the years6. 
 
The initial goal of this work was to create a possibility for the clinical 
implementation of the thrombin generation assay. The experience gained from 
this work led us to take a step back and identify the sources of variability in the 
thrombin generation assay, to use this knowledge for the proposition of solutions 
and to integrate this in the design of a method which is robust enough for clinical 
implementation. 
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The coagulation system 
 
This text is aimed at giving an overview of the coagulation system within which 
new insights can be incorporated. The description leaves room for the ambiguities 
of the coagulation system where many of its components have multiple, and 
sometimes contradictory functions in maintaining the dynamic balance of 
haemostasis.  
 
Ever since the first description of pathological haemostasis by Huang Ti in 
approximately 2650 B.C7, the coagulation system and many of its intricacies and 
interactions have been the topic of (scientific) research. Despite this early 
observation, it was not until a couple of thousand years later that a more 
deliberate investigation led to further insight in the formation of venous thrombi. 
One of the earliest aetiologies stems from Wiseman (1686) with his description of 
venous occlusion by blood clots through both stasis and hypercoagulability8. 
 
Throughout the last decades our understanding of the system and the interactions 
of its constituents has become broader and broader, thanks to advances in 
technology facilitating more sophisticated approaches. 
 
It is now known that the blood coagulation system consists of a series of zymogens 
and their pro/cofactors, most of which circulate in an inactive form. Thrombin 
(FIIa) is the central enzyme within this system9. It is, amongst other things, 
responsible for the cleavage of fibrinogen to fibrin, the main constituent of a blood 
clot. Thrombin is formed after the cleavage of its zymogen prothrombin (FII). The 
level of conservation of thrombin throughout evolution highlights the importance 
of prothrombin in coagulation and ultimately in survival. The sequence identity 
between human and hagfish (one of the oldest ancestors still in existence, dating 
back some 300 million years) is 53%10. 
 
Prothrombin is converted into thrombin after it has been cleaved at two different 
sites11. At the onset of coagulation only a small amount of thrombin is needed to 
form a blood clot. These trace amounts of thrombin assist in the formation of 
larger amounts of thrombin via several feedback mechanisms by which it enhances 
its own propagation. Besides stimulating its own formation, thrombin also 
activates its own inhibitors. These inhibitors put a halt to the formation of 
thrombin, ensuring containment of the process of coagulation.  
 
There are several ways in which coagulation can be initiated e.g. by a rupture of an 
atherosclerotic plaque or by a wound that ruptures a vessel12. When the vessel 
wall is damaged, it exposes the blood to TF, a protein bound to the membrane of 
perivascular cells. This prompts circulating factor VII (FVII) to bind the membrane 
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adjacent the now exposed TF. In circulation FVII already has some activity, but 
when it interacts with TF this activity is greatly intensified13. Through this 
interaction FVII is now able to activate the proenzyme factor X (FX). Activated FX 
(FXa) in turn, is able to fully activate FVII into FVIIa hereby speeding up its own 
formation even more. These feedback reactions lead to an explosion of active 
proteins.  
 
FXa is able to convert prothrombin into meizothrombin, which is an active form of 
thrombin that remains membrane bound14,15. Being membrane bound, 
meizothrombin is in a perfect position to activate co-factor V (FV) that binds the 
membrane as well. Activated FV (FVa) forms a complex with FXa and calcium on a 
phospholipid surface16 The formation of this so called prothrombinase complex 
increases the activation of prothrombin over a 1000 times compared to FXa 
alone17,18. The accelerated cleavage by the prothrombinase complex leads to a 
burst of thrombin.  
 
With such a prolific burst of procoagulant activity, it is easily understood that 
inactivation of the coagulation system is just as crucial in maintaining a 
haemostatic balance as activation is. The coagulation system is best viewed as a 
dynamic equilibrium that is allowed to fall to one side in case of e.g. injury, but 
which is rapidly restored when coagulation is no longer necessary. When FXa 
circulates freely, it quickly interacts with a protein called tissue factor pathway 
inhibitor (TFPI). This FXa - TFPI complex is an excellent inhibitor of the TF-VIIa 
complex19,20. Moreover, FVa (when it is not bound to a membrane) is also a potent 
inhibitor of the TF-VIIa complex21. Therefore, FXa and FVa propagate their own 
generation when bound to a membrane and they become inhibitors of coagulation 
when in solution.  
 
This very efficient inhibitory mechanism only allows FXa to be active for a brief 
period of time. Consequently, coagulation would not be able to reach the explosive 
state under low TF conditions, if it were not for an additional pathway. This 
pathway named the Josso loop22 after its discoverer François Josso (1927-1981), is 
triggered by the FVII-TF complex through the activation of FIX. Activated FIX (FIXa) 
is able to activate FX when it is bound to a phospholipid membrane and when it is 
in complex with activated factor VIII (FVIIIa), this FIXa-VIIIa complex is also known 
as the “tenase complex”23 24. 
 
Factor VIII (FVIII) is present in plasma bound to von Willebrand factor (VWF). As 
long as FVIII is bound to VWF it is unable to bind to a phospholipid membrane and 
form a complex with FIX. Thrombin is necessary to cleave FVIII upon which it loses 
its affinity for VWF. When FVIIIa is in solution, it can bind to phospholipids17. Unlike 
the activation of FV by meizothrombin, the activation of FVII requires thrombin in 
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solution, that, unlike meizothrombin, is at risk of being cleared by antithrombin 
(AT), particularly in the presence of heparin.  
The combination of both pro- and anticoagulant characteristics of FXa and FVa, 
ensures that coagulation takes place where it is necessary: on damaged cells and 
platelets where the procoagulant membranes are found. The spatial delineation of 
coagulation is further aided by TM, which is expressed on the surface of intact 
endothelial cells25. Thrombin that is bound to TM is able to cleave protein C (PC) to 
its activated form (APC), and due to this action thrombin loses its procoagulant 
properties26.  
 
APC is a strong inhibitory protein that, with the help of protein S and FV27,28, is able 
to degrade FVa and FVIIIa which are bound to procoagulant phospholipid 
surfaces27,29. When the procoagulant surface is provided by platelets APC is not 
able to effectively cleave FVa30, in fact platelets seem to protect FVa from cleavage 
by APC31. This specificity has led to the believe that APC is not necessarily 
responsible for the delimitation of thrombin formation but rather that it is 
responsible for the prevention of clotting on intact vasculature32. Compared to APC 
protein S has a greater inhibitory potential, as it is able to inhibit the 
prothrombinase complex on endothelial cells as well as on a platelet surface33. 
 
APC is cleared from the bloodstream by the serine protease inhibitor (serpin) 
protein C inhibitor (PCI). PCI is a very indiscriminative inhibitor which has in fact a 
higher affinity for other coagulation factors e.g. FXa, thrombin and FVIIa-TF than 
for APC34.  
Fibrin was initially named antithrombin 135 because it binds thrombin strongly. It 
has been shown that fibrin(ogen) is primarily a protector of thrombin activity, 
because of the limited access of α2macroglobulin (α2-M) to thrombin that is 
adsorbed to fibrin36. The most obvious antithrombin action of fibrin and probably 
the most teleological "reason" that a clot forms as soon as a trace of thrombin is 
formed, is that the clot is a spatial delineator. The structure of the clot prevents 
thrombin being washed from where it is most needed, or to spread in free solution 
where it can work disasters37 
 
The blood platelets play a major role in coagulation in vivo. Due to the complexity 
of their role, this will not be described in detail here. For a comprehensive review, 
please refer to the subchapter on platelets in Versteeg et al.32. In brief, the role of 
platelets in coagulation starts when endothelium damage occurs. Upon damage, 
platelets are triggered to adhere to the wound and to each other. Several 
mechanisms are responsible for the increased platelet adhesiveness, amongst 
others: shape change, clustering of receptors and increased receptor expression32. 
Aggregating platelets also actively participate in coagulation. From the moment 
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they are triggered to aggregate, some platelets are activated and start to express 
phosphatidylserine on their surface38,39, thereby providing a procoagulant surface. 
As was explained earlier, many coagulation proteins bind to such procoagulant 
phospholipid membrane layers where they react with other coagulation proteins. 
However, the existence of non-obstructive thrombi in large vessels is an indication 
that the forming plug, at some point, loses its propagating capabilities. This 
retardation of the growth of the plug is a phenomenon that is still poorly 
understood. 
 
Platelets and the coagulation system are closely intertwined and their functions 
are not those of two separate processes. The group of Bruce and Barbara Furie 
showed that the formation of fibrin takes place within 15s after a lesion is made in 
the vessel wall40. This rapid formation of fibrin indicates that thrombin must have 
been present almost at the onset of the formation of the platelet aggregate. This is 
further exemplified by the fact that it takes platelet poor plasma between 12-15s 
to clot at optimal TF concentration. Wherever there is fibrin, thrombin must have 
been present at ~15s before its appearance to provide the feedback reactions for 
coagulation to accelerate. Their exact role is still the subject of debate, but it has 
been shown that microparticles do play a role in coagulation as well41. It has been 
argued that they adhere to a site of lesion before platelets and they are 
instrumental in generating thrombin42.   
 
Further undermining the paradigm of primary haemostasis by platelets the 
bolstering of a primary plug by thrombin reinforces the idea that platelet 
aggregation is one voice in a concert of interactions involving plasma proteins and 
structured elements. Moreover, platelets play a vital role in the localization of 
coagulation at the site of injury. The confinement of the platelet aggregate reduces 
molecular transport rates within its core. This increases the concentration of 
soluble agonists which accelerate thrombin formation and subsequent platelet 
activation. Local accumulation of thrombin and the regulation of the density of 
platelet packing both contribute to thrombus growth. Moreover, the higher 
transport rates in the more permeable outer shell of the aggregate facilitate 
clearance and limit thrombin formation43.  
 
The large amount of thrombin localized in the clot activates thrombin-activatable 
fibrinolysis inhibitor (TAFI)26. TAFI protects degradation of fibrin by cleavage of the 
C-terminal residue, thereby protecting fibrin from degradation by plasmin27. This 
feedback mechanism leads to the formation of a specific clot morphology, that is 
dependent on the amount of thrombin in the clot. A lot of thrombin gives a dense 
network of thin fibrin fibres, whereas a small amount of thrombin gives a coarse 
network of thick fibres46,47. 
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Given the efficiency of all of these procoagulant processes it is not hard to imagine 
that there are counteracting forces present as well. Several have been mentioned 
already, but the main custodians are the antithrombins. The antithrombins present 
themselves to thrombin as a substrate to be cleaved, but after doing so thrombin 
finds itself to be stuck and incapable of further action35,48. The most important of 
the antithrombins was traditionally called antithrombin III (ATIII), and is 
responsible for clearance of about 2/3 of the total amount of thrombin49. The 2nd 
most important antithrombin is α2-M that clears about 1/4 of the total amount of 
thrombin50, the remaining fraction is cleared by miscellaneous inhibitors. Because 
there are so many antithrombins, we hesitate to follow the official nomenclature 
and will speak of “antithrombin III” when referring to the main antithrombin.  
 
The efficiency of ATIII is enhanced a great deal by heparin (a common 
anticoagulant drug). Heparins are glycosaminoglycans that consist of chains of 
alternating residues of d-glucosamine and uronic acid, glucuronic acid or iduronic 
acid51. Along the chain of saccharides, every 50-100 sugar units a specific sequence 
of 5 saccharide units occurs that has the ability to strongly bind ATIII52, which 
brings about a conformational change in ATIII that enhances its activity. Thrombin 
binds loosely anywhere to the saccharide chain without the need for a specific 
saccharide sequence. It moves quickly along the chain by lateral diffusion and so 
will meet-up with ATIII more easily, so much more easily in fact that heparin can 
increase the inhibition rate a thousand fold53. 
 
Measuring the coagulation system 
 
A concise overview of the coagulation tests used in the clinic is given by Bates and 
Weitz54. Although the paper was published in 2005, the text is still very 
representative of the current situation in the clinical coagulation laboratory. The 
overview below gives a concise summary of the work of Bates with a few additions 
in the case of newly implemented test. The main aim of the representation of the 
tests below is to stress that these tests and their results do not represent the 
entirety of the coagulation system.  
 
Most coagulation tests are defective approximations of a (specific) part/function of 
the coagulation system. They rather emphasize the initiation mechanism instead of 
the integral system of thrombin production. When rigorously standardized a 
clotting time, like the prothrombin time (PT) can be quite useful, e.g. in the 
monitoring of anticoagulant therapy with vitamin K antagonists55. The activated 
partial thromboplastin time (aPTT) defies all standardisation efforts56 and is 
unsuitable for the monitoring of heparin therapy57. 
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It is their representation of the initiation phase that makes clotting times inept for 
testing conditions that depend on the production phase of thrombin generation, 
i.e. thrombotic tendency or bleeding tendency dependent upon the amount of 
thrombin formed. In order to represent the entirety of the complex system, a test 
is required that goes beyond the initiation phase. That the amount of thrombin is 
important follows e.g. from the thrombotic tendency that occurs when the protein 
S dependent system fails (by the use of oral anticonception or factor V Leiden). 
Why the amount of thrombin is important may be due to various causes, such as 
e.g. insufficient defence against fibrinolysis through lack of TAFI activation.  
 
Despite the specific nature of the tests described below, they are at times applied 
for the detection of other pathologies than those described here. It is not 
impossible to do so, but it has to be understood that value of the results of an 
assay that measures the starting mechanism of coagulation only, is very limited in 
describing the complexity of a system as a whole. Most of the current coagulation 
tests operate in the same general principle as depicted with the APTT below. The 
variations can be found in the contents of the test tube with differing reagents or 
by the use of whole blood or blood plasma. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 1 Activated partial thromboplastin time (APTT).  
Sample used: Citrated PPP, Activator: FXII activator e.g., kaolin, ellagic acid, celite or silica + 
diluted phospholipids (cephalin) and calcium, Used for:  FVIII, FIX, FXI, FXII, HK, prekallikrein, 
FX, FV, FII, and/or fibrinogen deficiencies and monitoring of intravenous unfractionated 
heparin. 
 
As can be observed in figure 1, a trigger (in this case a mixture of phospholipids, 
calcium and kaolin) is added to platelet poor plasma. This sets in motion a series of 
reactions that ultimately lead to the formation of a clot. A photo sensitive optic, 
that is able to record the disturbance in the light detects the clot at which moment 
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the test stops and the time is recorded. As noted before, the tests described below 
are all clotting time tests and a apply a similar principle but differ in their trigger as 
well as reaction substrate. 
 
• Prothrombin t ime (PT) , Sample used:  Citrated PPP, Activator: 
Recombinant or purified TF Used for:  FII, FV, FVII, FX and fibrinogen 
deficiencies54,58. Vitamin K def. and fibrin degradation products. Warfarin, 
acenocoumarol, and fenprocoumon therapy through the INR. 
• Activated c lott ing t ime (ACT), Sample used: Whole blood Activator: 
Kaolin, celite or glass particles Used for:  High dose heparin treatment or 
bivalirudin treatment. Notice:  besides systems using optical detection, devices 
that apply electro-chemical detection of thrombin cleaving an electro-chemical 
substrate are available on the market as well59.  
• Thrombin c lott ing t ime (TCT), Sample used:  Citrated PPP Activator: 
Thrombin Used for:  Low fibrinogen, dysfibrinogenemia or elevated fibrinogen 
degradation products. 
• Ecarin c lott ing t ime (ECT), Sample used:  Citrated PPP Activator: Purified 
meizo-thrombin activator from the venom of the Russels viper (Echis 
Carinatus) Used for: Treatment with direct thrombin inhibitors60. 
 
Apart from these clotting time tests, there are other specific coagulation test that 
are currently use. Most of these apply different methods of detection making it 
difficult to cluster them. The “other tests” are usually methods to determine a 
single element (factor) of the clotting system (Fibrinogen or factors VIII or IX for 
the management of haemophilia), tests designed for measuring specific 
anticoagulant treatment (e.g. anti-factor Xa activity for heparins) or indicators of 
ongoing coagulation (D-dimers, TAT-complexes). They will not be further discussed 
here. 
 
Most tests that are being used in the clinic have faced the challenge of 
standardisation. Standardizing tests is crucial to get consistent results but has 
proven to be difficult for any clinical test and coagulation tests are no exception to 
this rule. One of the main contributors to the high inter-laboratory variability, of 
what can be considered a “simple” coagulation test like e.g. a clotting time, has 
been the composition of the reagents. In an attempt to standardize the PT the 
International Normalized Ratio (INR) has been established by the world health 
organization (WHO)61. Without this effort of standardization, PT results using 
different reagents cannot be compared62. However, despite the stringent 
standards, unreliable reporting of the international sensitivity index (ISI) by 
thromboplastin manufacturers63 and the variation in precision of INR 
determination as a result of different reagent and coagulometer combinations still 
causes variation of the results between laboratories. 
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Most research laboratories, do not have to abide to the stringent clinical 
requirements. Therefore, researchers have much more tools at its disposal to 
measure the coagulation system. Coagulation tests in the research laboratory 
range from specific test for platelet function to rheology or flow measurements. 
The present work however is restricted to the thrombin generation test. Thrombin 
being responsible for the “final” step of the coagulation system with the cleavage 
of fibrinogen to fibrin is dependent upon the interactions of the preceding proteins 
for its formation. Therefore, measuring thrombin formation over time gives an 
indication of the functioning of the system as a whole, way beyond the formation 
of a clot which already appears when only ~5% of all thrombin is formed. This 
broader view generated by the TG test gives it the potential to provide qualitative 
and quantitative information about the coagulation system as a whole. 
 
Throughout the last decades considerable evidence has been published that the 
amount of thrombin activity that develops in a sample of clotting blood(-plasma) is 
an indicator of the risk of bleeding64–67 as well as venous thrombosis68–76. 
Moreover, it relates to the risk of arterial thrombosis, be it in a less straightforward 
manner77–79. It is a common denominator of the effect of all anticoagulants80–87 
and, when it is measured in platelet rich plasma, it is inhibited by platelet 
inhibitors88,89. Therefore, it has a promising outlook for use as a clinically useful 
parameter. 
 
Similarly to the more basic clotting time based assays, the Calibrated Automated 
Thrombin Generation test (CAT-TG)3 that has been used in research laboratories 
for over 15 years now, has its share of difficulties with respect to standardization 
and reproducibility of the results between different laboratories.  
 
This poor inter-laboratory variability is considered to be the main issue preventing 
broad clinical implementation of TG-test6. The high variability in test results 
between laboratories has been attributed to e.g. a lack of automation and its 
sensitivity to pre-analytical variables90. Rigorous standardization of the pre-
analytical and analytical procedure and normalization relative to a reference 
plasma indeed improved the CV91,92. Moreover, a multicentre study from French-
speaking countries (France, Belgium, Switzerland) carried out under “real life” 
conditions in clinical and research laboratories showed that the use of a common 
reference plasma could improve inter-laboratory variability of most TG parameters 
except in cases of frank hypo-coagulability 93. These efforts have as yet not added 
up to a test which is sufficiently robust to warrant broad acceptation in the clinical 
laboratory.  
 
Measuring thrombin generation 
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Thrombin generation (TG) was first described in 1953 by MacFarlane and Biggs as a 
whole blood test94. In the same edition of the same journal Pitney and Dacie 
described the test in recalcified plasma95. Both methods were triggered by adding 
preheated calcium to a sample of clotting blood or plasma, out of which, individual 
timed (sub)samples were then taken at regular intervals. The subsample then is 
transferred to a test-tube with a fibrinogen preparation and the clotting time is 
recorded. The relation between clotting time and thrombin concentration has 
been previously established. From the observed clotting times the formation and 
subsequent decay of thrombin in these samples is then calculated. Despite its 
labour intensiveness this TG test, sometimes in a personalized version, has proved 
itself useful in advancing research in e.g. haemophilia96,97.  
 
Before TG could be more widely adopted, the test had to be fundamentally 
altered. In the present situation of the clinical chemistry lab, where laboratory 
work is reduced to putting samples in an automaton and waiting for the figures 
that it prints out – in this ambiance anything looking remotely as a subsampling 
experiment is an anachronism. A fundamentally new approach was required. This 
came in three concurrent steps. The first was from S. Béguin who added a 
chromogenic thrombin substrate directly to the clotting plasma. The second from 
C. Hemker, who realized that, if this were to reflect the complete thrombin 
generation curve, the substrate used should be so poorly reactive to thrombin that 
it should not be consumed during the course of the thrombin generation, and the 
third from R. Wagenvoord who suggested that – in order to be able to know what 
reaction velocity reflects what thrombin concentration, a calibration experiment 
had to be run in parallel. The combination of these three ideas allowed continuous 
measurement of thrombin formation98. In this way, through the detection of the 
reaction product that is cleaved from this substrate by thrombin, the formation 
and subsequent decay of thrombin in a plasma sample can be measured over time. 
Because the formation of fibrin disturbs the detection of the reaction product, the 
plasma has to be defibrinated prior to the measurement, or a fibrin polymerization 
inhibitor had to be added. 
 
Fibrin, however, is an essential part of the thrombin generation mechanism36 so it 
was an essential step forward when the fluorogenic substrates brought an end to 
this inconvenience. This led to the presentation of Calibrated Automated 
Thrombography (CAT)3.  
 
The idea of using a fluorogenic substrate not being patented it could be followed in 
the Technothrombin TGA method99. The simultaneous calibration through a 
parallel experiment had been patented, however, so that accurate calibration in 
the latter method will have to wait for the patent to expire. 
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The use of both chromogenic and fluorogenic substrates has led to a bifurcation in 
the commercially available thrombin generation assays. Currently there are three 
automated TG assays available, two that use the fluorogenic substrate: ST-Genesia 
by Diagnostica Stago, Inc. (Asnieres sur Seine, France), the CEVERON alpha TGA by 
Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH (Vienna, 
Austria) and the Behring Coagulation System (BCS) Siemens Healthcare GmbH 
(Erlangen, Germany), using a chromogenic substrate.  
 
Because of the important role of fibrin in physiological thrombin generation we 
restricted our research to methods using a fluorogenic substrate. The article by 
Kintigh et al99 is referred to for a comparison between the three automated assays.  
Besides the three automated methods for TG, four semi-automated TG assays 
exist. The same bifurcation as with the automated methods persists here with two 
assays using a chromogenic substrate and two using a fluorogenic substrate. The 
assays using a fluorogenic substrate can be seen as predecessors of the ST-Genesia 
and the Ceveron alpha TGA, as this method of TG is the further focus of this work 
they will be elaborately discussed below.  
 
But first, a brief review of the two assays that make use of the chromogenic 
substrate: HemoScan Thrombin Generation Assay (HemoScan, Groningen, The 
Netherlands), is a kit that is intended to measure the influence of biomaterials on 
thrombin generation. A plasma sample is exposed to the biomaterial to be 
investigated, where after the TG results with and without exposure are compared. 
The method utilizes subsampling, rather than continuous detection. After the 
sample is taken from the reaction mixture, the reaction is stopped and the formed 
thrombin is left to react with a chromogenic substrate. The thrombin 
concentrations in the subsamples are subsequently determined from a calibration 
curve. The HemoScan assay serves its purpose but is not intended for diagnostic 
use. 
 
Pefakit in-TDT (Pentapharm, Aesch, Switzerland), triggers thrombin generation by 
contact activation. The cleavage of a chromogenic substrate is subsequently 
detected over time by measuring the optical density of the reaction mixture. A 
fibrin polymerization inhibitor is added so as to prevent the formation of a fibrin 
clot and the related optical disturbance of the measurement. After taking the first 
derivative of the data this method determines two parameters: the lag-time and 
the peak. The results are not calibrated against a standard concentration of 
thrombin, rather the values for the patient sample are expressed as a percentage 
of normal.  
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The CAT assay measures thrombin generation in a sample of platelet poor plasma 
(PPP) or platelet rich plasma (PRP)3 and has been further developed to be used in 
whole blood100. The TG experiment is based on the detection of the reaction 
product of a ZGGR-AMC substrate by thrombin. The amount of thrombin in the 
sample in which thrombin is generating (the staple sample), is calculated by 
comparison to the fluorescence that develops in a separate sample of the same 
plasma in which a constant known amount of thrombin activity converts the 
substrate (the calibrator sample). In this way, the value of the calibration factor 
can be used to calculate the concentration of thrombin. How this is done and how 
it should be done is the main subject of this thesis. Figure 1a displays a typical 
fluorescence trace of such experiment. The speed with which thrombin is formed 
over time (i.e. the first derivative of the original curve) gives a rough approximation 
of the thrombin generation curve (figure 1b) and allows to distinguish the separate 
phases of the process: the lag-time (1), the burst of thrombin formation (2) and 
thrombin decay (3). It can also be noticed is that the curve does not return to the 
x-axis due to residual thrombin activity of the α2-macroglobulin thrombin (α2M-T) 
complex. Thrombin entrapped in the α2macroglobulin molecule loses all known 
physiological activity but still can split small substrates. This phenomenon and how 
to disentangle it from real thrombin activity will be discussed in more detail in 
following chapters. 
 
 
Figure 2 thrombin generation data.  
A, “raw” fluorescence trace of thrombin generation. B, First derivative of A with lag-time 
“1”, thrombin formation “2”, and thrombin decay “3”. 
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The reaction velocity during the experiment is not determined by the 
concentration of thrombin (and (α2M-T) alone, also the concentration of substrate 
plays a role here. Because during the reaction the substrate is consumed the same 
amount of thrombin will not cause the same reaction velocity in the beginning of 
the experiment and later on.  
 
Also, the relation between fluorescence and concentration of product is not linear. 
The consequences of substrate consumption and inner filter effect and how to 
correct for them will be discussed in much detail in the following chapters. Here 
we only stress the unique feature of the CAT-method, i.e. that for each TG-
experiment there is a parallel calibration experiment in which, in the same plasma, 
the same amount of substrate is converted by a known fixed amount of thrombin 
activity (in the form of the (α2M-T complex)101. This provides a sample-specific 
calibration factor at every level of fluorescence and therefore in principle allows 
correct determination of thrombin concentrations. How to carry out such 
calculations and searching for alternative but equally correct methods of 
calibration is the main subject of this thesis.  
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Abstract 
 
Background Measuring thrombin generation (TG) in plasma increasingly gained 
attention as a diagnostic tool in the field of thrombosis and haemostasis. To 
include the contribution of all blood cells, recently the whole blood TG method 
was developed.  
 
Methods We changed the calculation method of the standard calibrated 
automated thrombography (CAT) to a method only considering the data until the 
peak of TG, thereby considerably reducing the time from blood draw to result. By 
redesigning the method, the blood volume per test was reduced to 15 µl.  
 
Results  For all TG parameters the inter-assay variation proved to be below 15%. 
The inter-individual variation of all parameters was comparable to the CAT 
method. 33 patients undergoing cardiothoracic surgery were included to 
investigate whether our assay correlates with post-operative blood loss. Upon 
dividing patients into severe and mild bleeders, significant differences between 
both groups were found for the peak endogenous thrombin potential (peakETP) 
and peak values determined by our near patient device. Importantly, patients with 
a peakETP below the median, experienced significantly more blood loss compared 
to those with a peakETP above the median. A similar division based on the peak as 
well as the body mass index of the patient yielded similar significant differences. A 
combination of the peakETP, the body mass index, and the lag-time even resulted 
in a better predictor of blood loss compared to each parameter separately.  
 
Conclusions Our adapted whole blood TG assay can be used near patients and is 
indicative for the amount of blood loss post cardiothoracic surgery. 
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Introduction 
 
The global haemostatic assay that measures thrombin generation (TG) in plasma 
increasingly gained attention as a diagnostic tool in the field of thrombosis and 
haemostasis. TG can be used to distinguish mild from severe bleeding phenotypes 
in haemophilia A patients with comparable factor VIII levels1. Conventional assays, 
such as the prothrombin time and activated partial thromboplastin time, are based 
on measuring clotting times. In vitro fibrin formation, however, occurs when less 
than 5% of the total amount of thrombin has been formed2. This indicates that the 
whole haemostatic capacity cannot be adequately evaluated by an endpoint 
clotting assay3,4.  
 
The calibrated automated thrombography (CAT)4 uses platelet-poor (PPP) or 
platelet-rich (PRP) plasma and a fluorogenic thrombin-sensitive substrate to 
determine the rate and extent of TG after initiation of coagulation. Coagulation is 
triggered with tissue factor (TF) (extrinsic pathway) or an intrinsic pathway initiator 
(e.g. kaolin or ellagic acid). Recently, the CAT-method was modified enabling the 
measurement of TG in whole blood by using a thin layer methodology5,6. By 
applying TG in whole blood, the assay includes the contribution of blood cells to 
coagulation. Moreover, avoiding the preparation of PRP or PPP our whole blood 
approach reduces the assay time and thereby the time it takes to get the patient’s 
result. Another advantage is that the method uses a low volume of blood per 
experiment6. Interestingly, these properties of the novel whole blood method 
allow the development of a near patient TG test. 
 
The key objective of near patient testing is to have a device that is able to generate 
results in an acceptable time, without the need of highly skilled laboratory staff7. 
As a result, appropriate treatment could be determined in a shorter time-period 
improving clinical outcome. Other global tests to study haemostasis (e.g. 
viscoelastic tests) are increasingly used in the diagnosis and treatment of 
coagulation abnormalities in critically ill patients8,9. In addition, the overall cost of 
such methods is considerably lower. Current haemostatic techniques for near 
patient clinical use include whole blood platelet function tests (aggregometry)10, 
viscoelastic tests of fibrin formation (thromboelastometry)11, activated clotting 
time and International Normalized Ratio measurements. However, each of these 
assays is limited in its ability to fully evaluate a patient's coagulation profile and 
hence prediction of bleeding risk or thrombotic complications.  
 
Near patient TG testing has been previously hinted12–15. First approaches were 
based on either an electrochemical principle14 or fluorescence principle15. To the 
best of our knowledge, none of these methods have been technically and clinically 
validated. In this paper, we report the development of a miniaturized whole blood 
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TG test and a quick thrombogram analysis. The clinical potential and practicality of 
the novel TG assay was tested in a population of patients (n=33) undergoing 
elective coronary artery bypass grafting (CABG), a vulnerable patient group in 
which post-surgical bleeding is a frequently occurring complication.  
 
Materials and methods 
 
Healthy controls  and patients  
After approval of the local medical ethical board (Medical Ethical Committee of 
Maastricht University Medical Centre) 5 healthy adult volunteers not taking any 
drugs for at least two weeks gave full informed consent according to the Helsinki 
declaration. Blood was collected aseptically by antecubital puncture into vacuum 
tubes (1 volume trisodium citrate 0.105M to 9 volumes blood) (BD Vacutainer 
System). The blood was kept at room temperature (21°C) and used within 4 hours 
after withdrawal. Platelet-poor plasma (PPP) was obtained by double 
centrifugation at 2630g for 10 min and stored at -80°C until further analysis. 
 
The cardiothoracic surgery study was approved by the local medical ethical board 
(Medical Ethical Committee of Maastricht University Medical Centre) and written 
informed consent was obtained from all volunteers. In total, 47 patients 
undergoing surgery for elective CABG were included. Exclusion criteria were age < 
18 years and duration of extra-corporeal circulation (ECC) < 60 min. 14 out of the 
47 patients were excluded, 12 of which had a duration of the ECC of < 60 min and 
2 underwent additional surgical procedures besides the CABG. Blood samples, 
taken at pre-bypass before heparin administration, were withdrawn from the 
arterial line after discarding the first 10 ml and collected into vacuum tubes (1 
volume trisodium citrate 0.105M to 9 volumes blood) (BD Vacutainer System). 
 
C l in ical  management 
After being connected to standard monitoring (electrocardiography, non-invasive 
blood pressure, pulsoximetry), all patients received a venous (Vasofix Safety, 16G, 
1.7×50 mm) and arterial line (Radial Artery Catheterization set, 20G, 1.1×44.5 mm 
Arrow International) with 2ml xylocaine 1% as local anaesthesia. Anaesthesia was 
introduced according to local standards (etomidate, sufentanil and rocuronium in a 
weight adapted dose) and patients were orally intubated. A large bore central 
venous line was placed in the right jugular vein and upon clinical need a TEE-probe 
was inserted for perioperative echocardiography. Anaesthesia was maintained by 
infusion of propofol 3-4 mg/kg/h and repeated injections of sufentanil boli 
according to the clinical need. Before initiation of cardiopulmonary bypass (CPB) 
anticoagulation was achieved by administration of 300-400 IU/Kg unfractionated 
heparin (Heparin Leo, Leo Pharmaceutical Products BV) to achieve an activated 
clotting time above 400 s. After termination of the CPB the initial heparin dose was 
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reversed with protamine in a 1:1 ratio. Components of the CPB system were poly-
2-methoxyethylacrylate coated (Terumo). The primer for the CPB circuit consisted 
of 1300 ml of 4% gelofusin, 200 ml 20% mannitol, 100 ml 20% human albumin, 50 
ml 8.4% NaHCO3 and 6500 IU unfractionated heparin. Patients were kept at 
normothermia (36°C) during CPB. Pericardial, pleural and residual blood of the CPB 
circuit was drained and washed with a cell saver device at the end of the perfusion. 
The transfusion trigger was set at a haematocrit below 23%. 
 
Pre-operative data collection included demographics and drug usage. Peri-
operatively, medication, infusion volumes, transfusion requirements, time on 
bypass, cross-clamping time, duration of the surgery, number of grafts, necessity 
of re-thoracotomy and blood loss were recorded. Post-operatively, the infusion 
volumes, transfusion requirements and the blood loss were recorded. The latter 
was assessed by the drainage amount of the chest tubes, which are inserted prior 
to closing the chest until 24 hours after surgery, when they are removed and the 
patient is discharged to the medium care (further referred to as “drainage 
volume”). 
 
Haematocrit ,  p latelet  counts and f ibr inogen concentrat ion 
measurements 
Haematocrit and platelet counts were determined using a coulter counter (Coulter 
LH750 haematology analyser, Beckman Coulter Inc.). Fibrinogen concentrations 
were determined using a coagulation analyser according to the manufacturer’s 
instructions (STA-R, Diagnostica Stago). 
 
Miniaturized TG device and microf luidic  chip 
The measurement module of the device is a dual canal fluorescence detector 
(ESELog, Qiagen Lake Constance, Germany). Due to its low operating voltage and 
lack of moving parts, the detector can easily be integrated into various 
measurement processes. The detector works with impinging light and is equipped 
with confocal optics. It is connected via a mini to micro-USB cable to an android 
smartphone equipped with dedicated software (Synapse BV, Maastricht, the 
Netherlands) for data collection (figure 1A). The detector, holder for microfluidic 
chip, and temperature control system are placed in a custom housing with 
dimensions 13×9×6 cm (figure 1A). Temperature (37˚C) control of the chip and its 
holder is performed with a foil heater, temperature sensor and controller (Minco, 
by Alflex the Netherlands). The TG reaction in whole blood is carried out in a 
microfluidic chip (figure 1B) moulded from methyl methacrylate-acrylonitrile-
butadiene-styrene (MABS) (chips are injection moulded by Mekora, Aachen 
Germany). The chip consists of two separately moulded pieces of MABS with a 
porous matrix disc of 5 mm in diameter and 160 μm thickness (589/1; Whatman, 
Germany) in their centre. Before assembly the part that bears the microfluidic 
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channels is treated with a plasma-cleaner (PDC-32G-2, Harrick Plasma, NY, USA) for 
15 minutes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Presentation of the near patient TG system.  
(A)  The image of the prototype device and connected smartphone with dedicated 
software. (B)  Image of an assembled (left) and disassembled (right) two-layer transparent 
microfluidic (MABS) chip with a porous matrix disc of 5 mm in diameter and 160 μm 
thickness. 
 
Near Patient TG Assay  
Citrated blood (15 μL) was mixed with 15 µL activator solution containing (ZGGR)2-
Rhodamine 110 (P2Rho), recombinant human tissue factor (TF; Innovin®, Dade 
Behring, Germany) and CaCl2 in 20 mM HEPES, 140 mM NaCl and 5 mg/mL bovine 
serum albumin (Sigma, the Netherlands) with a pH of 7.35. The P2Rho was a kind 
gift of Diagnostica Stago, (France). The final concentrations are 50% volume blood, 
1 pM TF, 16.7 mM CaCl2, and 300 μM P2Rho. To calibrate the fluorescence signal, a 
second measurement was performed in which 5 μL P2Rho and 10 μL 
α2macroglobulin-thrombin (α2M-T) complex (prepared as previously described16) 
were added to the blood. The final thrombin activity at 100 nM was used for 
calibration of the experiments. The fluorescence signal was recorded with γex = 485 
nm and γem = 538 nm. The assay was performed at 37°C.  
 
Models  for  Thrombogram Analysis   
The traditional CAT algorithm describes the thrombin generating capacity of a 
person from a thrombogram, using the parameters thrombin peak height (peak, 
nM), area under the curve (ETP, endogenous thrombin potential, nM.min), time to 
reach 5 nM of thrombin (lag-time, min), and time-to-peak (ttpeak, min)4. The time-
consuming nature makes the CAT method unsuitable for fast near patient testing. 
We assumed that the sigmoidal part of the fluorescence curve, until its inflection 
point, provides relevant information regarding the thrombin generating capacity of 
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a person. The sigmoidal part of the curve was fitted with a flexible, extended 
Chapman-Richards growth (CRG) equation, F=a(1-e-bt)c+d(1-e-ft)17, where F is the 
fluorescence intensity at time t and a, b, c, d, f, and g are the parameters that 
determine the shape of the curve. Subsequently, the peakETP (area under the 
curve until the peak is reached), peak, lag-time, and time-to-peak (ttpeak) were 
calculated from the first derivative of the simulated curve. 
 
PPP CAT 
PPP CAT was performed as previously described4. Briefly, the CAT assay was 
measured in a pre-heated plate fluorometer (Ascent reader, Thermolabsystems 
OY, Helsinki, Finland). To each well, 80 μl of plasma was added in combination with 
the TF trigger (final concentration 1 pM) and phospholipid vesicles (20 mol% 
phosphatidylserine, 60 mol% phosphatidylcholine and 20 mol% phosphatidyl-
ethanolamine from Avanti) at a final concentration of 4 μM in Hepes-buffered 
saline. 
 
Stat ist ics  
Statistical analysis was performed with SPSS version 21 (IBM, Inc). Results are 
expressed as mean and standard deviation (SD). Data were checked for normality 
and the Spearman or Pearson correlation was calculated accordingly, to verify the 
association between different parameters. In addition, patients were divided into 
two groups based on the median of each of the TG parameters, clinical parameters 
or median drainage volume. Resulting groups were compared for drainage volume 
and other laboratory/clinical parameters using the Mann-Whitney U test for 
independent samples for scale variables and the Fisher’s exact test for nominal 
variables.  
 
Results 
 
Comparison of  calculat ion methods 
To validate the CRG model-based data analysis procedure, we compared the 
thrombogram parameters calculated with the CRG model to those obtained with 
the CAT-based calculation method18,19. Citrated blood from one subject was 
activated with TF (5 pM) and CaCl2 (16.7 mM) in the presence of 300 µM P2Rho. 
The increase in fluorescence intensity was recorded over time using the CAT. The 
CAT-based analysis is displayed in figure 2A. The calibrator data represent the 
cleavage of substrate by a known amount of α2M-T (solid line). The fluorescence 
intensity from the experimental mixture (dotted line) was converted in a thrombin 
concentration using the calibrator. In figure 2B the first derivative of the calibrated 
curve shows the generation of free thrombin in molar concentration (solid line), 
after correction for the formation of α2M-T complex (dotted line), that still cleaves 
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the substrate but does not represent free thrombin activity. This method covers all 
coagulation stages, including initiation, propagation and termination of TG. 
 
Secondly, the same set of raw data, but only until the inflection point of the 
sigmoidal curve was fitted using the Chapman-Richard function17. In figure 2C, the 
calibrator data (solid line), the raw data points (dotted line), and the results of the 
fit (solid red line) are displayed. In figure 2D the goodness of the fit is determined 
by the difference between the experimental and fitted data. The sum of these 
differences constitutes the total error of the fit. In figure 2E the first derivative of 
the calibrated, fitted data gives the total amount of free thrombin in molar 
concentration, until the peak value of the TG curve.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. TG curves determined using the CAT method (A,B) and the CRG method (C-E).  
Citrated whole blood from a healthy donor was triggered with 5 pM TF, 16.7 mM CaCl2 in 
the presence of 300 µM P2Rho. The fluorescence intensity was recorded in triplicate 
measurements. (A)  The raw calibrator data (solid line) and raw TG data (dashed line) are 
shown. (B) The first derivative of the corrected and calibrated curve (solid line) after 
correction for the α2M-T complex formation (dashed line) is shown. (C) The raw calibrator 
data (solid line), the raw experimental TG data (dashed line) are shown up to the inflection 
point, together with the fitted data using the CRG model (red solid line). (D) The residues, 
C	A	
B	 E	
D	
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(Fexp-Ffit)
2 resemble the goodness of the fit. (E) The first derivative of the CRG simulated 
curve until the inflection point is shown. 
 
Thrombogram parameters were calculated for both the CAT and CRG method, and 
this approach was repeated for 4 additional healthy individuals. To compare the 
thrombogram parameters obtained with both models, correlation coefficients 
between each of the TG parameters of the two calculation methods were 
calculated and were 0.868, 0.998, 0.993 and 0.981 for the (peak)ETP, peak, lag-
time and ttpeak, respectively. 
 
The CRG model only considers the data until the peak is reached. Therefore, the 
peakETP calculated with the CRG model provides limited information about the 
termination phase of TG, resulting in a relatively lesser correlation with the ETP 
parameter of the CAT model.  
 
Inter-assay precis ion 
The assay was tested for its accuracy in measuring the calibration factor for which 
the rate of increase of fluorescence intensity (FU/min) can be converted in molar 
amounts of thrombin. Citrated blood from one subject was repeatedly (n=10) 
mixed with α2M-T (100 nM) in the presence of 300 µM P2Rho. Under the 
experimental conditions used, we found that during the assay time (10 min), the 
fluorescence intensity increased linear in time during the full course of the 
experiment. The coefficient of variation between the 10 calibrator measurements 
proved to be 13.8%. 
 
Similarly, re-calcified citrated blood from the same healthy subject was repeatedly 
(n=10) assayed for its TF-induced (1 pM TF) thrombin generating capacity. The 
resulting thrombogram parameters, displayed as mean ± SD (CV) are shown in 
table 1. The inter-assay variation of the 5 healthy individuals that were measured 
to determine the inter-individual variation, as well as that of the 33 patients 
included for the clinical evaluation, was < 11% for all of the TG parameters. These 
results are comparable with previously published inter-assay precision in the whole 
blood CAT6. Intra-assay precision could not be assessed, as we are restricted to 
measuring one sample at a time. Moreover, inter-assay precision was not 
determined over a time period longer than 1 day due to the storage limitations of 
whole blood.  
 
Inter- indiv idual  var iat ion 
The thrombin generating capacity of TF-activated re-calcified citrated blood from 5 
healthy subjects was measured in triplicate. The mean and SD for the different 
parameters between the 5 subjects are displayed in table 1. The inter-individual 
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variation of the TG parameters obtained with our new device are comparable to 
those of the whole blood CAT6.  
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Table 1. Inter-individual and inter-assay variation in TG parameters.  
For the inter-individual variation 5 healthy subjects were tested using the near patient TG 
device; for the inter-assay variation 1 healthy subject was tested 10 times. TG parameters 
were determined using the CRG model  
 Inter- indiv idual  
var iat ion N = 5 
Inter-assay variat ion N 
= 10 
Parameter Mean±SD %CV Mean±SD %CV 
peakETP (nM.min) 154.7±34.3 22 133.5 ± 19 14 
Peak (nM) 116.5±26.2 22 102.5 ± 11.9 12 
Lag-time (min) 3.18±0.4 13 2.6 ± 0.2 8 
ttpeak (min) 5.8±0.4 7 5.1 ± 0.4  8 
 
Near patient whole blood TG in patients undergoing cardiothoracic  
surgery 
To test the applicability of our new method, we studied 33 patients scheduled for 
CABG with the use of a heart lung machine for extracorporeal circulation. To 
compare the results obtained with our new method to the golden standard in TG, 
measurements were also performed in PPP. Patients were divided in two groups 
based on the median of drainage volume, resulting in a group of ‘severe’ and ‘mild’ 
bleeders. General patient characteristics, as well as pre- and post-operative 
variables of all groups are shown in table 2 in the supplemental information. A 
statistically significant difference was found between the two groups for the 
peakETP and the peak of the near patient data and for the ETP of the PPP data. The 
resulting parameters displayed as mean ± SD per group with their respective P-
value are for the peakETP 162.8 ± 38.1 versus 120.3 ± 35.9 (P = 0.002), the peak 
136.7 ± 40.4 versus 106.0 ± 29.6 (P = 0.011) and the ETP (PPP) 1244.5 ± 274.1 
versus 1025.1 ± 216.4 (P = 0.017) for the severe versus mild bleeders, respectively. 
Other parameters that differed significantly between the two groups include the 
patient’s weight (87.9 ± 10.9 versus 76.1 ± 13.9; P = 0.015), their BMI (29.1 ± 2.3 
versus 25.1 ± 3.9; P = 0.001), and the administered volume of colloids during the 
first 24h on the intensive care unit (21.4 ± 10.8 versus 9.2 ± 6.4; P < 0.001).  
 
Alternatively, to determine the predictive potential of different parameters for 
bleeding, patients were divided in two groups based on the median of the general 
characteristics, the peri- and post-operative variables, and the clinical 
characteristics. Next, the difference in drainage volume, was compared between 
these two groups (table 3 in the supplemental information). A statistically 
significant difference in drainage volume was found when patients were divided 
based on the median BMI, post-operative colloid administration, the peakETP, the 
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peak parameters of the near patient data, and the pre-operative fibrinogen 
concentration. Individual data of the drainage volume for the two groups stratified 
according to the median of the peakETP and BMI are shown in figure 3A, and 
figure 3B, respectively. Interestingly, the combination of peakETP, lag-time and 
BMI further enhanced the prediction of the drainage volume (figure 3C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Drainage volume in patients undergoing cardiothoracic surgery stratified 
according the median peakETP (A) as assessed by our near patient device, the median BMI 
(B), and a combined parameter based on the peakETP, lag-time and BMI (C).  
33 patients undergoing cardiothoracic surgery were divided into two groups based on 
either the median peak-ETP (A), BMI (B), or a combined parameter based on the peakETP, 
lag-time and BMI. Individual values of drainage volume are shown, together with the mean 
± SEM. * p<0.05, ** p<0.005, and *** p<0.001 (Mann-Whitney U test) 
 
Discussion 
 
The present study demonstrates the technical development and clinical testing of 
a whole blood TG method as a near patient test. Our new whole blood device is 
characterized by a good technical performance, comparable to the standard CAT 
method. The high turnover time (up to 60 min) is still a major bottleneck for the 
current TG20. Not only have we been able to reduce the size of the device, with our 
CRG calculation model we decreased the turnover time of our new test to less than 
20 min. To achieve the short measurement time, an altered calculation method is 
needed, only considering the data until the peak of the TG curve.  
 
We tested the clinical applicability of the device in a population of patients N = 33 
undergoing elective CABG. These patients are known to have a high bleeding risk 
due to the invasive nature of the surgery21,22. The extracorporeal circulation is 
believed to be one of the main contributors to the bleeding risk. The circuit causes 
major haemostatic disturbances e.g. due the dilution of coagulation factors as a 
result of the priming fluid of the machine23,24. Currently there are no tests available 
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that accurately predict the risk of blood loss of a patient planned to undergo 
surgery. The coagulation tests that are performed pre-operatively are mainly used 
to identify coagulation disorders that increase the risk of peri-operative bleeding25. 
However, these tests lack the sensitivity to pick up subtle inter-individual 
differences between patients that do not have any obvious coagulopathy. The 
more recently emerged viscoelastic tests for near patient testing, including 
thromboelastography and rotational thromboelastometry, are primarily used to 
aid in the selection of the optimal allogeneic blood products or coagulation factor 
concentrates during/after clinical bleeding20. However, these viscoelastic tests 
have little predictive value in terms of peri-operative blood loss26,27. 
 
TG measurements in plasma proved to be indicative for blood loss in patients 
undergoing CABG28,29. Despite the relatively small number of patients included, our 
study confirms these results, as patients with a volume below the median drainage 
volume, were characterized by a significantly lower ETP in plasma. Dividing 
patients based on the median of the drainage volume, also resulted in significant 
differences in peakETP and peak determined by the near patient whole blood TG 
device, as well as the BMI. This is in accordance with other studies that have shown 
that patients with a lower BMI are at a higher risk regardless of the type of cardiac 
surgery with CPB30,31.  
 
To determine the predictive capacity of our near patient measurements, we 
divided patients based on the median of pre- and postoperative determined 
parameters, and compared the drainage volume between both groups. 
Interestingly, patients with a peakETP below the median, experienced significantly 
more drainage volume compared to those with a peakETP above the median. 
Moreover, a division based on the peak data of our new device resulted in a similar 
significant difference between the two groups.  
 
Besides our near patient TG parameters, the BMI was a predictive indicator for the 
amount of drainage volume when subjected to this form of analysis. Interestingly, 
the combination of the peakETP, the lag-time, and the BMI of the patient, proved 
to be a better predictor of the drainage volume than each parameter separately. In 
accordance with previous results, the pre-operative fibrinogen concentration 
shows a similar trend32.  
 
We do acknowledge the limitation of the study size and understand that, despite 
the statistical significance, this study should be extended to larger patient 
populations. Additionally, further clinical studies are necessary to determine its 
importance in the monitoring and therapeutic guidance of other bleeding and 
thrombotic pathologies. A possible limitation of our device is that, due to the 
external mixing of reagents, a technician and laboratory environment are still 
Near Patient Thrombin Generation in Patients Undergoing Elective Cardiac Surgery 
	 41	
necessary. We are currently busy with the implementation of the reagents in the 
chips. Furthermore, we are optimizing a quality control that can be run daily to 
verify proper functioning of the device. Before implementation of the device in 
clinical settings, the effect of common interferents such as bilirubin, lipid particles 
and commonly co-administered drugs should be further investigated. Of note, the 
haemoglobin and creatinine levels pre-surgery did not correlate with the pre-
surgery TG parameters (data not shown). Indirect effects of co-administered drugs 
and other surgery-specific effects should be assessed prior to clinical use of our 
device. In this study, the patient group was too small to draw any conclusions 
regarding these effects. Of course, anticoagulant drugs will have an influence on 
the outcome of our test as they influence the coagulation system of the patient. 
Usually, patients are asked to discontinue this medication before surgery, but any 
remaining of these medications will influence TG and hence blood loss.  
 
Importantly, despite the small sample size and the described limitations, our data 
suggest an added clinical value for our TG device being indicative of the bleeding 
risk after cardiac surgery. A test, such as the near patient TG, that can be 
performed in the vicinity of the patient and hence gives a fast result, has the added 
benefit that treatment can be initiated faster. This in turn makes the treatment 
more effective as time is of utmost importance in a clinical setting33. Ultimately, 
after further validation and simplification, our device may be suitable for use 
outside a laboratory/hospital environment e.g. in the general practitioner’s office. 
This will reduce the number of routine hospital visits and therewith improve the 
quality of life of patients. 
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Supplementary information 
 
Table 2. Distribution of patient characteristics, peri- and post-operative variables. Patients 
are divided into two groups based on the median of the drainage volume. Group 1 had a 
drainage volume of < 780 ml group 2 had a drainage volume > 780 ml.  
 
Variable Al l  patients Group 1 Group 2 P-value 
 
N=33 N=17 N=16 
Mann-
Whitney U-
test / 
 
Mean SD Mean SD Mean SD 
Fisher’s 
exact test 
General characteristics 
       
Age (years) 66.8 8.7 67.1 10.0 66.5 7.5 0.958 
Gender (% female) 24% 35% 13% 0.225 
Length (cm) 173.6 7.8 173.5 7.6 173.8 8.5 1.000 
Weight (kg) 82.2 13.6 87.9 10.9 76.1 13.9 0.015 
BMI 27.2 3.7 29.1 2.3 25.1 3.9 0.001 
Intraoperatively 
       
Heparin-total (IU/kg) 94.6 59.1 99.2 75.3 89.8 36.8 0.510 
Protamin-total (mg/kg) 3.6 0.5 3.4 0.4 3.8 0.6 0.087 
Tranexamic acid (mg/kg) 36.8 13.2 32.7 6.0 41.2 17.1 0.063 
Crystalloids (ml/kg) 14.7 9.8 11.6 7.2 17.3 11.5 0.168 
Colloids (ml/kg) 0.7 1.7 0.7 1.5 0.7 1.9 1.000 
Total packed cells (ml/kg) 0.6 2.1 0.2 0.9 1.1 2.9 0.736 
FFP (ml/kg) 0.0 0.0 0.0 0.0 0.0 0.0 NA 
Platelet concentrates (ml/kg) 0.3 1.3 0.0 0.0 0.7 1.9 0.557 
Fibrinogen (mg/kg) 1.3 5.4 0.0 0.0 2.6 7.7 0.557 
Fluid in Cell Saver (ml) 439.2 230.2 474.9 240.0 401.3 220.8 0.345 
Fluid in Ultrafiltration (ml) 333.3 578.1 317.7 604.4 350.0 568.0 0.873 
Time on bypass (min) 82.0 17.3 81.1 17.6 83.1 17.5 0.557 
Time X-clamping (min) 59.3 16.1 59.2 17.1 59.4 15.6 0.790 
Duration surgery (min) 205.0 45.0 205.5 49.8 204.6 40.9 0.763 
Number of CABG 3.6 1.1 3.4 1.3 3.9 0.8 0.465 
Postoperatively 
       
Crystalloids (ml/kg) 27.8 10.0 26.5 9.1 29.3 11.0 0.276 
Colloids (ml/kg) 15.1 10.7 9.2 6.4 21.4 10.8 0.000 
Total packed cells (ml/kg) 3.6 7.3 0.4 1.1 6.9 9.5 0.053 
FFP (ml/kg) 1.0 3.5 0.0 0.0 2.0 4.9 0.363 
Platelet concentrates (ml/kg) 1.0 2.2 0.0 0.0 2.0 2.8 0.068 
Fibrinogen (mg/kg) 3.2 10.2 0.0 0.0 6.5 14.1 0.363 
Re-thoracotomy (% of patients) 9% 0% 18.8% 0.103 
Laboratory parameters before 
surgery        
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peakETP (nM.min) 142.2 42.4 162.8 38.1 120.3 35.9 0.002 
peak (nM) 121.8 38.4 136.7 40.4 106.0 29.6 0.011 
lag-time (min) 3.2 0.5 3.2 0.4 3.3 0.5 0.309 
ttpeak (min) 5.3 0.7 5.3 0.7 5.3 0.7 0.958 
PPP ETP (nM.min) 
1138.
1 
268.2 1244.5 274.1 1025.1 216.4 0.017 
PPP peak (nM) 267.4 75.6 286.6 78.5 246.9 69.0 0.094 
PPP lag-time (min) 4.2 1.9 4.4 2.0 4.0 1.9 0.231 
PPP ttpeak (min) 6.4 2.3 6.6 2.5 6.2 2.2 0.363 
Fibrinogen concentration (g/L) 3.6 0.8 3.9 0.9 3.4 0.6 0.127 
Blood loss 
       
Blood loss during surgery (ml) 
1514.
6 
699.0 1529.4 586.5 1499.0 821.5 0.465 
Drainage volume (ml) 928.2 485.3 585.0 123.8 1292.8 459.1 0.000 
Total blood loss (ml) 
2442.
8 
894.2 2114.4 517.1 2791.5 
1080.
9 
0.031 
BMI, Body Mass Index; CABG, Coronary Artery Bypass Grafting; ETP, Endogenous Thrombin 
Potential; ttpeak, time-to-peak; FFP, Fresh Frozen Plasma; SD, standard deviation. 
 
Table 3. Distribution of the drainage volume. Patients are divided into two groups based on 
the median of the indicated parameter. 
 
Variable < Median > Median P-value 
 
N=17 N=16 
Mann-Whitney U-
test 
 
Mean SD Mean SD 
 
General characteristics 
     
Age (years) 944.7 580.2 910.6 377.7 0.683 
Length (cm) 1025.0 598.6 825.3 313.6 0.557 
Weight (kg) 1030.9 521.5 819.1 433.3 0.157 
BMI 1103.2 484.3 742.19 424.9 0.005 
Intraoperatively 
    
 
Heparin-total (IU/kg) 825.6 407.7 1037.2 548.2 0.276 
Protamin-total (mg/kg) 943.4 481.3 913.8 503.4 0.929 
Transexamin acid (mg/kg) 771.5 275.5 1094.7 603.4 0.136 
Crystalloids (ml/kg) 933.2 514.0 922.8 569.7 0.736 
Fluid in Cell Saver (ml) 928.2 302.9 928.1 635.1 0.231 
Time on bypass (min) 814.7 344.9 1048.8 587.7 0.292 
Duration X-clamping (min) 898.8 470.9 959.9 513.7 0.736 
Duration surgery (min) 887.1 385.1 971.8 583.3 0.958 
Number of CABG 778.8 302.9 1086.9 593.6 0.118 
Postoperatively 
    
 
Crystalloids (ml/kg) 862.4 464.8 998.1 511.7 0.382 
Colloids (ml/kg) 738.2 313.1 1130.0 559.9 0.019 
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Laboratory parameters before 
surgery 
     
peakETP (nM.min) 1086.5 480.3 760.0 444.7 0.006 
peak (nM) 1049.7 476.3 799.1 475.3 0.031 
lag-time (min) 856.2 536.3 1004.7 428.3 0.094 
ttpeak (min) 897.9 539.8 960.3 435.3 0.309 
PPP ETP (nM.min) 1070.3 558.3 777.2 350.3 0.118 
PPP peak (nM) 1024.1 573.6 826.3 360.5 0.382 
PPP lag-time (min) 932.9 408.9 923.1  569.2 0.510 
PPP ttpeak (min) 968.2 388.7 885.6 580.9 0.146 
Fibrinogen concentration (g/L) 1114.4 565.8 730.3 282.6 0.034 
Blood loss      
Blood loss during surgery (ml) 914.7 366.7 912.0 612.0 0.136 
Total blood loss (ml) 726.2 236.7 1142.8 589.3 0.041 
BMI, Body Mass Index; CABG, Coronary Artery Bypass Grafting; ETP, Endogenous Thrombin 
Potential; ttpeak, time-to-peak. 
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Abstract 
 
Background To better understand hypercoagulability as an underlying cause for 
thrombosis, the leading cause of death in the Western world, new assays to study 
ex vivo coagulation are essential. The zebrafish is generally accepted as a good 
model for human haemostasis and thrombosis, as the haemostatic system proved 
to be similar to that in man. Their small size however, has been a hurdle for more 
widespread use in haemostasis related research.  
 
Methods In this study we developed a method that enables the measurement of 
thrombin generation in a single drop of non-anticoagulated zebrafish blood. 
Scanning electron microscopy for the visualization of the fibrin network. 
 
Results  Pre-treatment of the fish with inhibitors of FXa and thrombin, resulted in 
a dose dependent diminishing of thrombin generation, demonstrating the validity 
of the assay. In order to establish the relationship between whole blood thrombin 
generation and fibrin formation, we visualized the resulting fibrin network by 
scanning electron microscopy.  
 
Conclusion Taken together, in this study we developed a fast and reliable 
method to measure thrombin generation in whole blood collected from a single 
zebrafish. Given the similarities between coagulation pathways of zebrafish and 
mammalians, zebrafish may be an ideal animal model to determine the effect of 
novel therapeutics on thrombin generation. Additionally, because of the ease with 
which gene functions can be silenced, zebrafish may serve as a model organism for 
mechanistical research in thrombosis and haemostasis. 
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Introduction 
 
Thrombosis remains a leading cause of death in the western world. Aside from 
mortality, significant morbidity occurs from thrombotic events. The causes of this 
hypercoagulability are becoming more and more clear with an enhanced 
knowledge of haemostasis and the development of new coagulation assays. Most 
of this knowledge results from extensive in vitro biochemical characterization of 
blood coagulation, whereas studies investigating blood coagulation in vivo are 
limited. 
 
Due to the availability of knockout technology, genetic studies of thrombosis in 
mice are popular. Nonetheless, the time consuming and labour-intensive process 
of generating knockouts restricts these studies. The zebrafish is generally accepted 
as a good model for mammalian haemostasis and thrombosis due to the presence 
of coagulation factors, platelet receptors and its response to anticoagulant drugs 
commonly used in clinical treatment1. In addition, haemostatic pathways in 
zebrafish proved to be similar to those in man2–4. Interestingly, the use of zebrafish 
enables large scale mutagenesis screening to identify novel genes involved in 
haemostasis and thrombosis5,6.  
 
The small size of zebrafish has been a hurdle in thrombosis and haemostasis 
research since most of the conventional coagulation assays require large amounts 
of plasma. Jagadeeswaran et al. optimized a total coagulation activity screening 
assay using small quantities of zebrafish plasma, by adding human fibrinogen and 
measuring fibrin formation by turbidimetry to probe thrombin formation7. 
Additionally, they developed an ultra-sensitive kinetic method to identify specific 
pathway defects in small quantities of plasma. Disadvantages of such assays 
include the requirement of multiple zebrafish and the use of plasma, not 
considering the effect of thrombocytes and erythrocytes on coagulation. 
 
At present, mainly end-point assays are used to detect coagulation defects. These 
assays simply measure the time it takes for a platelet-poor plasma sample to clot, 
i.e. when the first traces of fibrin are formed. However, fibrin formation already 
starts in the presence of tiny amounts of thrombin (≈1 nM)8. Thus, the vast 
majority of thrombin takes place after fibrin formation9, suggesting that clotting 
time-based assays only measure the initiation and not the propagation phase of 
coagulation. Importantly, correct functioning of the haemostatic system proved to 
be dependent on the total amount of thrombin that is formed during 
coagulation10. We recently developed a reliable method to measure thrombin 
generation in a drop of whole blood, thereby bringing coagulation one step closer 
to physiology11. In this study, we further optimized this method enabling the 
determination of thrombin generation in a drop of non-anticoagulated whole 
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blood obtained from a single zebrafish. Thrombin generation proved to be 
sensitive to pre-treatment of the fish with inhibitors of FXa and thrombin. 
Furthermore, we visualized the resulting fibrin network by scanning electron 
microscopy (SEM) in order to analyse the density and dimensions of the fibrin 
strands. 
 
Materials and methods 
 
Reagents 
20 mM Hepes buffer (pH 7.35) containing 5 mg/ml bovine serum albumin (BSA) 
and 140 mM NaCl (BSA5) or 60 mg/ml bovine serum albumin (BSA60) were 
prepared as described previously12. The rhodamine-based substrate P2Rho was a 
kind gift of Diagnostica Stago. The calibrator, α2macroglobulin-thrombin (α2M-T) 
complex was prepared in-house as described previously12. Rivaroxaban (Xarelto) 
was from Bayer and melagatran was a gift from AstraZeneca.  
 
B lood col lect ion and treatment of  zebraf ish 
This study was carried out in strict accordance with the recommendations in the 
guide for the use of laboratory animals of the university of Liège. The protocol was 
approved by the committee on the ethics of animal experiments of the university 
of Liege Permit number LA 1610002. Blood was collected from adult (male and 
female) wild type zebrafish (Danio rerio) as described previously7. Briefly, with a 
small pair of scissors, an incision was made at the lateral side of the fish just 
posterior of the dorsal fin, thereby transecting the dorsal vein/artery. From the 
blood welling up in the wound, 5 µl was collected for further analysis. 
 
For anticoagulant treatment, fish were sedated with a high dose of tricaine 
solution (1.6 mg/ml). Fish were dried with paper and weighed. Only fish weighing 
less than 1 gram were used and injected intraperitoneally with 20 µl/g of the 
indicated anticoagulant in phosphate buffered saline (PBS) and 0.25% phenol red 
(to monitor the injection process). After injection, fish were allowed to recover for 
30 minutes after which blood was collected as described above. 
 
Thrombin generation measurement 
For thrombin generation, an adapted protocol was developed based on our whole 
blood thrombin generation assay11. Collected whole blood (5 μl ) was mixed with 5 
μl of HEPES buffer containing the P2Rho substrate (final concentration (fc) 300 
μM). 5 μl of this mixture was put on a paper disk and covered with mineral oil to 
prevent evaporation. The lag-time phase of the thrombin generation experiment 
was started as soon as the incision for the blood withdrawal was made. Calibration 
was done by adding 5 μl of whole blood to 5 μl of HEPES buffer containing P2Rho 
(fc 300 μM), α2M-thrombin calibrator (fc 100 nM) and citrate (fc 9,8 mM). 
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Fluorescence was recorded with a fluorescence detector (ESElog, Qiagen) with λex 
= 485 nm and λem = 538 nm. All experiments were performed at 37°C. 
Analysis of the fluorescence tracings to yield the thrombogram and corresponding 
parameters was performed with a modified method, considering only the 
thrombin generation until the peak is reached. From the resulting thrombogram 
the following parameters were calculated: lagtime (min), peak (nM, maximal 
thrombin concentration), peak-endogenous thrombin potential (ETP, nM.min, area 
under the thrombin curve until the peak is reached), time to peak and velocity 
(nM/min, maximal rate of thrombin generation). 
 
The human samples were analysed using the plasma CAT as previously described12 
in the presence or absence of either rivaroxaban or melagatran. 
 
P lasma samples for  normal pool  p lasma 
After approval of the local medical ethical board (Medical Ethical Committee of 
Maastricht University Medical Centre) 24 healthy adult volunteers who did not 
take any drugs for at least two weeks gave full informed written consent according 
to the Helsinki declaration. Blood was collected aseptically by antecubital puncture 
into vacuum tubes (1 volume trisodium citrate 0.105M to 9 volumes blood) (BD 
Vacutainer System).  
 
For the normal pooled plasma (NPP), blood from the 24 volunteers was prepared 
by centrifuging the blood at 2900g during 10 min at room temperature. Plasma 
was aspirated and the procedure was repeated. Plasmas were pooled and further 
ultra-centrifugation (100000g, 70 min) was carried out. Aliquots of 1 ml were 
stored at -80°C until use. 
 
SEM analys is  
After thrombin generation was determined in whole blood, the clots were 
prepared for visualization by SEM. The clots were fixated by adding 2.5% 
glutaraldehyde (grade I, Sigma Aldrich, St. Louis, Missouri) in PBS (Sorensen’s, pH 
7.2) (Electron Microscopy Sciences, Hatfield, PA, USA) for 1 hour at room 
temperature and then placing it at 4°C overnight. The following day, the 
glutaraldehyde solution was removed and the samples were repeatedly (5x) 
washed with PBS. As a secondary fixation, the samples were placed in 
osmiumtetroxide (OsO4, 1%) diluted in sodium cacodylate (200 mM, pH 7.4) 
(Electron Microscopy Sciences, Hatfield, PA, USA) for 1 hour at room temperature. 
Consecutively, the clots were dehydrated in ethanol (30%, 50%, 70%, 90% and 3 
times at 100%) for 3 minutes. The samples were then treated with a 
hexamethyldisilane/ethanol solution for 3 minutes and in hexamethyldisilane 
(Sigma Aldrich, St. Louis, MO, USA) for 10 minutes. The samples were removed 
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from the wells, left to dry and coated with gold. Analysis was performed on a 
desktop SEM (Phenom-World, Eindhoven, the Netherlands). 
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Stat ist ical  analys is  
For statistical analysis of the data GraphPad Prism Software was used. Differences 
between two groups were evaluated by the one-way ANOVA test or the Mann 
Whitney U test. 
 
Results 
 
Development of  an assay to measure thrombin generation in  
zebraf ish 
In a first set of experiments, thrombin generation was determined in 5 µl whole 
blood collected from single zebrafish, using a method comparable to whole blood 
calibrated automated thrombography11. The limited blood volume of a single 
zebrafish, impedes the performance of both a thrombin generation and calibrator 
measurement. Since calibrator measurements performed on the blood of 28 
different fish in 5 independent experiments demonstrated an acceptable variation 
(mean CV of 14%), the average calibrator slope per experiment was used for 
thrombin generation calculations.  
 
Subsequently, thrombin generation was measured in 5 independent experiments, 
each consisting of 3 to 5 thrombin generation measurements. Thrombin 
generation curves, together with the average and %CV of the individual thrombin 
generation parameters are shown in figure 1. The thrombin enzyme from zebrafish 
clearly proved to be capable of cleaving our rhodamine-based substrate. 
Interestingly, thrombin generation measured in individual fish showed a similar 
amount of inter-individual variation as in humans11. Striking differences with 
human thrombin generation include the much shorter lag-time, and the increased 
peak height and velocity index. Taken together, our results demonstrate the 
feasibility of measuring thrombin generation in whole blood collected from a single 
zebrafish.  
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Figure 1. Thrombin generation curves and parameters in zebrafish.  
Thrombin generation was measured in 5 independent experiments, in a total of 25 
zebrafish. (A)  Thrombin generation curves are shown. Each colour represents an 
independent experiment. (B)  Mean thrombin generation parameters and their CV are 
calculated. 
 
In a next set of experiments, the effect of pre-treatment of the zebrafish with 
thrombin or FXa inhibitors on thrombin generation parameters was tested. 
Zebrafish were treated with the indicated compounds and doses for 30 minutes as 
mentioned before, followed by blood collection and thrombin generation 
measurements. Thrombin generation curves of the individual zebrafish are shown 
in figure 2. Results are expressed as the percentage inhibition compared to a 
control group of vehicle-treated fish (n = 8) and are representative for 2 
independent experiments.  
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Figure 2. Inhibition of thrombin generation in zebrafish by thrombin or FXa inhibition.  
Zebrafish were treated with Melagatran (A)  or rivaroxaban (B)  at the indicated doses for 
30 min, followed by thrombin generation measurements. (C)  Results are expressed as the 
percentage inhibition compared to a control group of vehicle-treated fish (n = 4). Results 
are representative for two independent experiments. Statistical differences between 
treatment and control groups were performed with *Mann-Whitney U-test or $1-way 
ANOVA. (ns = not significant) 
 
As to the thrombin inhibition, treatment with melagatran concentrations above 0.5 
µg/g completely blocked thrombin generation, clearly illustrating that the 
observed fluorescent signal is thrombin- related. A concentration of 0.1 µg/g 
melagatran significantly inhibited thrombin generation, as evident from the 
significantly decreased peak height and reduced lag-time, time to peak and 
velocity index. The dosage needed to inhibit thrombin generation in zebrafish was 
considerably lower than concentrations used in in vitro experiments with normal 
pooled plasma. In these experiments a concentration range of 1073 to 3575 µg/g 
was needed to get a dose dependent inhibition of thrombin generation. 
Comparable results were obtained upon injection of another thrombin inhibitor, 
hirudin (4 µg/g) (data not shown). Additionally, inhibition of FXa by rivaroxaban 
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treatment (concentrations of 1 and 10µg/g) resulted in a similar inhibition of the 
thrombin generation. The concentration was in contrast with the in vitro results in 
normal pooled plasma, in which lower concentrations from 72,65 µg/g rivaroxaban 
already resulted in inhibition of thrombin generation. However, the dosages used 
in the zebrafish were much closer to the prescribed dose for adults of 20 mg/day 
(± 0.29 µg/g) 
 
SEM analys is  of  f ibr in c lots   
Given the accelerated and increased thrombin generation in zebrafish compared 
to humans, we decided to analyse the fibrin ultrastructure at the end of a 
thrombin generation experiment by SEM. The mineral oil that was used to prevent 
evaporation was removed and the fibrin that was formed was fixated for 
visualization with SEM. A representative image of the fibrin network is shown in 
figure 3. Analysis of the clot revealed a much denser network compared to 
humans, composed of thin fibrin fibres. Interestingly, the structure of the network 
is comparable to a human fibrin network triggered with high tissue factor 
concentrations (data not shown). The entrapped red blood cells and thrombocytes 
in the fibrin network, might suggest their participation in the process of 
coagulation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Scanning electron microscopy (SEM) of zebrafish blood clots. (A)  
Representative image of SEM analysis of blood clots formed during thrombin generation 
measurements. (B-C) Sequential enlargements of the fibrin network with entrapped red 
blood cells. Arrows in (C)  indicate platelets.  
 
Discussion 
 
In this study, we optimized an assay to measure thrombin generation in whole 
blood obtained from a single zebrafish. A major advantage compared to previous 
tests, is the use of whole blood instead of plasma, resulting in a quick and reliable 
screening tool to measure blood coagulation in zebrafish. Furthermore, as the 
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measurement starts directly after the blood collection, the use of an anticoagulant 
that may influence coagulation is avoided.  
 
The suitability of the zebrafish model to study haemostasis depends hugely on the 
degree of similarity between the zebrafish and mammalian systems. Previous 
studies have established that, despite the evolutionary distance, the major 
coagulant and anticoagulant pathways are similar between zebrafish and 
mammalians, as evident from the presence of a comparable contact activation 
system, extrinsic pathway and common pathway3. The effects of prothrombin 
deficiency in zebrafish embryos, ranging from early morphological defects and 
internal bleeding to occasional bleeding in the brain at a later stage, suggest that 
the mechanism of thrombin signalling is conserved across vertebrates13. To our 
knowledge, our method is the first that allows measurement of thrombin 
generation in whole blood obtained from a single zebrafish. Thrombin generation 
experiments in zebrafish showed a similar inter-individual variation as in humans11. 
However, thrombin generation proved to be significantly accelerated and 
increased compared to humans. With the current blood collection method, using a 
pair of scissors, exposure of the blood to tissue factor is inevitable. Therefore, the 
current method is suits well for tests related to the intrinsic coagulation system. 
 
By pre-treating zebrafish with thrombin inhibitors, we clearly provided evidence 
that the observed fluorescent signals in our assay are the result of thrombin. The 
treatment with thrombin inhibitors, hirudin and FXa was found to significantly 
inhibit thrombin generation in zebrafish. Hirudin microinjections into early 
zebrafish embryos were previously shown to inhibit fibrin forming activity and to 
cause abnormal development, suggesting a role for thrombin in early 
development14. Furthermore, Jagadeeswaran et al. demonstrated that warfarin 
has similar effects in zebrafish compared to mammals, illustrating that vitamin K-
dependent pathways in fish are comparable to human pathways3,7. Interestingly, 
as all tested anticoagulant therapy was found to diminish thrombin generation in 
zebrafish, zebrafish may be used as an in vivo model system to test the 
pharmacokinetic and pharmacodynamic aspects of (novel) therapeutics on 
thrombin generation. 
 
As to the fibrin formation, the appearance of a dense fibrin network composed of 
thin fibrin fibres is in line with the accelerated and increased thrombin generation. 
Indeed, high versus low concentrations of thrombin lead to dense networks of thin 
fibres versus permeable clots composed of thick woven fibrin strands, 
respectively8,15,16.  
 
In conclusion, we developed a fast and reliable method to measure thrombin 
generation in whole blood collected from a single zebrafish. Given the huge 
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similarities between coagulation pathways of zebrafish and mammalians, zebrafish 
may be an ideal in vivo model to determine the effect of novel therapeutics on 
thrombin generation. Additionally, because of the ease with which gene functions 
can be silenced, zebrafish may serve as a model organism for further mechanistical 
research in thrombosis and haemostasis.  
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Abstract 
 
Background The thrombin generation capacity of plasma is an important 
determinant of the individual thrombotic or bleeding tendency, which makes it a 
promising clinical variable. At this moment however, its implementation in routine 
clinical practice is hindered by a relatively high variability between different 
laboratories. Efforts to improve this variability by normalisation have improved the 
comparability of some parameters and yet worsened others.  
 
Methods we analysed 34 sets of fluorescence curves of the same sample of 
reference plasma that were obtained under “real life” conditions in 12 different 
clinical laboratories throughout France, Belgium and Switzerland.  
 
Results  Our analysis revealed two major sources of inter-laboratory variability: 
Errors due to the calibration procedure and errors due to insufficient temperature 
control. About 30% of experimental variation can be attributed to the former and 
about 20% to the latter.  
 
Conclusions Elimination of these errors reduces the total inter-laboratory 
variability of the area under the thrombin generation curve from 16.3 to 8.1% and 
that of the peak thrombin activity measured from 17.4 to 8.6%. 
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Introduction 
 
Thrombin generation,  potentia l  benefits  of  i ts  introduction into 
c l in ical  pract ice 
Measuring the thrombin level in clotting plasma is an established tool in blood 
coagulation research since around 1950 but the technique was too laborious for 
routine clinical use1,2. The evolution of the method to the continuous 
measurement of thrombin by its cleavage of an added fluorogenic substrate 
increased throughput to around 24 samples per hour3,4. The increased throughput 
triggered a widespread interest in this approach. Throughout the last decades 
considerable evidence has been published that the amount of thrombin activity 
that develops in a sample of clotting blood(-plasma) is an indicator of the risk of 
bleeding5–8 as well as venous thrombosis9–17. It also relates to the risk of arterial 
thrombosis, be it in a less straightforward manner18–20. It is a common 
denominator of the effect of all anticoagulants21–28 and, when it is measured in 
platelet rich plasma, it is inhibited by platelet inhibitors29,30. Therefore, it has a 
promising outlook for use as a clinical parameter.  
 
In calibrated automated thrombography (CAT) the amount of thrombin in the 
sample in which thrombin is generating (the staple sample), is calculated by 
comparison to the fluorescence that develops in a separate sample of the same 
plasma in which a constant known amount of thrombin activity converts the 
substrate (the calibrator sample). In this way, the value of the calibration factor 
(CF) can be read at every level of fluorescence. The same plasma needs to be used 
in both the thrombin generation (TG) and the calibrator experiment because e.g. 
the colour of individual plasmas influences fluorescence in a different way. 
 
Inter- laboratory var iabi l i ty  as  an obstacle for  c l in ical  implementation 
The main issue preventing broad clinical use of TG is the relatively high inter-
laboratory variability of its results31. This has been attributed to a lack of 
automation and because of its sensitivity to pre-analytical variables32. Rigorous 
standardization of the pre-analytical and analytical procedure and normalization 
relative to a reference plasma indeed improved the CV33,34. A multicentre study 
from French-speaking countries (France, Belgium, Switzerland) carried out under 
“real life” conditions in clinical and research laboratories showed that the use of a 
common reference plasma could improve inter-laboratory variability of most TG 
parameters except in cases of frank hypo-coagulability35. In the present work, we 
utilized the original fluorescence traces from the common reference plasma used 
in this study to investigate possible causes of the observed variability. 
 
It has been observed that TG is “inversely” temperature sensitive: the lower the 
temperature, the higher the thrombin activity found36. Consequently, the TG test is 
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critically dependent upon the preheating of the samples: insufficient preheating 
makes the temperature rise during the first minutes of the measurements, leading 
to an underestimation of the calibrator activity, hence causing an overestimation 
of the CF, and finally resulting in an underestimation of the thrombin 
concentration. Moreover, the temperature equilibration process largely coincides 
with the lag-time in the test sample, and thus is certain to influence this variable. 
In so far as it extends beyond the lag-time, insufficient temperature control will 
influence the course of TG as well. The combination of underestimation due to 
delayed heating of the calibrator and enhancement of TG due to delayed heating 
of the test sample will result in unpredictable overestimation of the recorded 
values of Endogenous Thrombin Potential (ETP) and Peak. 
 
The aim of the current study was to evaluate the sources of inter-laboratory 
variation and to quantify the sources of the variability, notably temperature. 
Moreover, its aim is to propose the most appropriate strategy for improvement of 
the assay. 
 
Materials and methods 
 
Data set descr ipt ion 
Graphs of fluorescence (in arbitrary units (AU)) against time of both calibrator 
curves and TG curves were kindly provided by the labs that partook in the study of 
Perrin35. In total we obtained the data of 34 separate experiments in which 
samples of the same reference plasma were measured in 12 different labs on 
different days. A detailed description of the experimental conditions and protocol 
can be found in the original article35. In short, a unique and common normal 
reference plasma (reference Plasma Stago®, Diagnostica Stago Asnières) was used 
in a standard TG experiment at 5pM tissue factor (TF) in 34 separate experiments 
performed in 12 laboratories. In the calibration experiments the α2macroglobulin-
thrombin complex (α2M-T), Thrombin Calibrator™ (Diagnostica Stago Asnières)) 
was added as the equivalent of constant thrombin activity. The different 
participating laboratories used different batches of calibrator. No instruction was 
given as to preheating of the plates prior to the measurement. The mean values, 
standard deviations and variation coefficients of thrombin generation parameters 
for initial data set can be found in table 1. 
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Table 1. Mean values, standard deviations and variation coefficients of TG parameters for 
initial data set. 
 ETP, 
nM·min 
Peak, nM ttpeak, 
min 
Lagtime, min 
Mean 1553.7 268.0 5.90 2.97 
Standard 
deviat ion 
252.8 46.5 0.48 0.35 
Variat ion 
coeff ic ient,  % 
16.3 17.4 8.2 11.7 
 
Temperature control  est imation 
The stability of the temperature throughout the experiment was assessed from the 
raw fluorescent data of the calibration curves by means of a specially designed 
program written by us in Mathematica 10.0 (Wolfram Research). The code of the 
program is provided in Supplementary materials. Its algorithm is based on the use 
of the graph of the first derivative of fluorescence (dF/dt) against the fluorescence 
(F) itself previously defined as the “diagnostic plot”37,38. At constant temperature 
dF/dt is highest at zero time (F0) because substrate concentration is highest and 
the inner filter effect is still absent (figure 1A). An increase of dF/dt in the 
beginning of the experiment can only be attributed to an increase of temperature. 
In case of a constant temperature, the shape of the diagnostic plot could be 
described by a decreasing branch of a parabola (for the rationale behind this see 
ref37).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Diagnostic plots for the calibration curves measured after 15 min of preheating 
(A) and after 2 min of preheating (B).  
Bold black point in section (B) corresponds to the end point of the “shaft” of the hockey 
stick. Δ is the difference between measured initial value of dF/dt and the value obtained 
from the extrapolation of the “shaft” to F0. 
 
The “hockey stick” is not a very precise metaphor here as the “shaft” is not 
straight, but we will still use it for the sake of visualization of the algorithm used for 
the evaluation of the magnitude of temperature changes. 
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When preheating of the samples is insufficient, it results in diagnostic plots with a 
characteristic “hockey stick” appearance (figure 1B). The initial uprising part of 
such a curve, representing the temperature relaxation process, corresponds to the 
“head” of the “hockey stick” and the descending part corresponds to its “shaft”. 
The “hockey stick” is not a very precise metaphor here as the “shaft” is not 
straight, but we will still use it for the sake of visualization of the algorithm used for 
the evaluation of the magnitude of temperature changes.  
 
For each diagnostic plot its part unperturbed by the temperature relaxation 
processes, i.e. the “shaft” of the hockey stick. The program selected the longest 
possible “shaft” on the diagnostic plot basing on the criteria that its initial point 
should lie inside standard deviation range of the residuals of a parabolic 
approximation fitted to the “shaft”. Afterwards the parabolic approximation of the 
“shaft” was extrapolated backwards to the initial zero time point to calculate the 
difference (Δ) between measured initial value of dF/dt and the value obtained 
from the shaft’s approximation (figure 2B). As an estimate of the temperature 
error we used the increase of the CF (CFinc) at the zero-time point calculated as the 
ratio of Δ to the value of dF/dt measured at the beginning of the experiment: 
 CF!"# = ∆!"!"|!!!       (1) 
 
Finally, for each set of TG curves measured in the same plate the quality of 
temperature control was estimated by the averaged value of CFinc calculated for all 
calibration curves present in that particular plate. 
 
Evaluation of  errors induced by cal ibrat ion 
During a TG experiment α2M-T forms from the interaction of the inhibitor α2-
macroglobulin (α2M) with thrombin. α2M is present in sufficient excess over 
thrombin, ~3 vs. 0.3 μM respectively to safely assume that the reaction is first 
order. The amount of α2M-T formed is therefore directly proportional to the 
amount of thrombin and to the time it is active i.e. the final α2M-T concentration 
is proportional to the ETP. The ratio of the α2M-T end level to the ETP therefore is 
in theory constant and should be independent of any error that could be 
introduced by calibration.  
 
We used this fact to remove the effect of possible calibrator activity errors. To this 
end we used the values of α2M-Tend as calculated by the Thrombinoscope® 
software to compare the individual α2M-Tend value to the average of all α2M-Tend 
values from the experimental data from the different laboratories combined. This 
comparison yielded a correction factor (R) that was applied to calculate an 
internally calibrated ETP (ETPic). So: ETPic = R·ETPexp where R = (Average α2M-Tend) / 
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(Experimental α2M-Tend). An analogous formula was used to calculate “internally 
calibrated Peak”. 
Results 
 
Continuous cal ibrat ion,  calculat ion of  free thrombin 
As explained under methods, it is possible to correct for calculation errors in the 
ETP via the ratio between the ETP and the end-level of α2M-T, because the 
proportion, to which ETP is over- or under-estimated by the calibration procedure, 
is the same as the proportion to which the final level of α2M-T is under- or 
overestimated. This property we used to correct the values of ETP and peak as 
described under methods. In table 2 it is seen in how far the experimental error is 
diminished by this procedure. In fact, the CV for the internally calibrated ETP is 
reduced by almost 30% as compared with the initial CV with a reduction from 
16,3% to 11,7%. A similar trend is observed for the thrombin peak in which the 
inter-laboratory CV is reduced from 17,4% to 11,9%. The remaining error must be 
the experimental error in the curve of amidolytic activity, fa(t), which includes the 
error due to insufficient temperature equilibration and possible errors in the 
calculation of ETP and α2M-T from the raw data38. 
 
Errors due to insuff ic ient temperature equi l ibrat ion 
For each experiment, the degree of the temperature control quality CFinc was 
calculated. The corrected values of ETP and Peak for all 34 experiments are plotted 
against CFinc (figure 2 C, D). The higher the temperature jump in the beginning, the 
lower the actual temperature was during the experiment. TG increases when the 
temperature decreases as can be seen when compared to figure 2 A, B; it is 
therefore not surprising to find higher TG values in the cases where there was a 
higher temperature jump. Figure 2 confirms this relation between TG parameters 
and CFinc. Moreover, this relation allowed us to subtract a temperature dependent 
trend from the data and evaluate the variability of the data after this second 
correction. 
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Figure 2. ETP and Peak versus temperature control estimation parameter CF-inc. (A, B) – 
initial values; (C, D) – values obtained after the elimination of calibrator activity errors. 
Moreover, this relation allowed us to subtract a temperature dependent trend from the 
data and evaluate the variability of the data after this second correction. 
 
Mean values, standard deviations and variation coefficients for corrected data are 
presented in table 2. In total the two successive correction procedures both for 
temperature and for calibration reduced the variability of ETP and Peak by nearly 
50%. 
 
Table 2. Mean values, standard deviations and variation coefficients for ETP and Peak, 
effect of temperature and calibration correction. 
  
  
ETP  Peak  
initial i.c. i.c.+t.c. initial i.c. i.c. + t.c. 
Mean 1553.7 1571.0 1371.0 268.0 270.5 236.0 
Standard 
deviat ion 252.8 183.5 111.3 46.5 32.3 20.3 
Variat ion 
coeff ic ient,  
% 16.3 11.7 8.1 17.4 11.9 8.6 
 
Discussion 
 
Normalizat ion  
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Normalization seems to be an effective way to reduce the inter-laboratory 
variation for the assay31,33,35,39. However, it does not seem capable to correct for all 
different parameters under all different conditions and the remaining variability is 
still relatively high ~10%39. Normalization could therefore only present a partial 
solution to the inter-laboratory variation for further clinical implementation, since 
its major drawback results in the persistence of the error in both the normal and 
test sample, which reduces both the sensitivity and specificity of the assay. Lastly, 
since normalization adds experimental conditions (as well as costs and time) to the 
assay by testing the reference plasma this may further increases the barrier for 
clinical implementation of TG.  
 
Cal ibrat ion 
The calibration procedure is necessary to relate observed reaction velocities 
(dF/dt) to thrombin concentrations i.e. to quantify the amount of thrombin that is 
formed during an experiment. The classical approach to calibration, is to 
determine a CF once and use this value for all subsequent time points and 
experiments. In TG experiments this approach is not feasible, as during the 
experiment the inner filter effect and substrate consumption continuously increase 
the CF. Therefore, at every level of fluorescence another CF applies. In the 
experiments shown here the CF increases by 45% from the beginning to the end of 
the experiments. Moreover, the lack of stability of the excitation beam gives 
erroneous fluctuations of the signal. These could also lead to discrepancies 
between a predetermined CF and the measured TG signal. Lastly the colour of the 
plasma leads to a difference in the signal intensity since there are plasma 
constituents that absorb the energy of the emission wavelength which differ from 
sample to sample. 
 
In the experimental procedure, the course of total amidolytic activity fa(t) is found, 
consisting of free thrombin fg(t) and thrombin bound to α2M. Because the velocity 
of formation of α2M-T in the pseudo first order reaction α2M + T → α2M-T is 
proportional to the concentration of free thrombin, with the reaction constant k as 
the proportionality constant, the total amount of α2M-T formed is k times the 
integral of the thrombin-time curve.  
 
The contributions of T and α2M-T apart thus can be calculated by numerical 
solution of the differential equation 𝑓! 𝑡 = 𝑓! 𝑡 + 𝑘 𝑓!(𝑡)𝑑𝑡!! . In the end 
(𝑡 → ∞) 𝑓!(𝑡)𝑑𝑡!! = 𝐸𝑇𝑃 and 𝑘 𝑓!𝑑𝑡!! = 𝑘 · 𝐸𝑇𝑃 is the end level of α2M-T.  
 
In this procedure, the correct k is that one that allows the boundary condition that 
free thrombin becomes zero without ever having been significantly negative. In 
practice, this means that the point in time has to be estimated at which all free 
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thrombin has disappeared. Various strategies can be employed that need not be 
discussed here; suffice it to say that the ideal solution has not yet been found. The 
essential point is that if k is underestimated, part of the activity of α2M-T is 
attributed to free thrombin and contributes to the ETP, whereas when k is 
overestimated part of the free thrombin is attributed to α2M-T. Variations in the 
estimation of K might contribute to the residual error after compensation for 
temperature and calibration effects. Improvement in reliability of the estimation of 
K could be achieved by mathematical smoothing of the raw data prior to analysis. 
 
Further reduction of the variability caused by calibration of the experiment can be 
sought in the internal calibration of the sample; for example, by utilizing the α2M-
T that is formed during the experiment. However, solutions that correct for the 
colour of the plasma and the inner filter effect have still to be found in order to be 
able to quantify the thrombin concentration in the sample in a reliable way. 
 
Temperature 
The variation that is introduced by temperature differences throughout the course 
of the experiment is at large an operator error. If the sample temperature is 
meticulously tuned to the temperature inside the fluorometer, and/or if the 
software in the fluorometer enforces the operator to pre-heat the sample long 
enough, the causes of the “hockey stick” disappear. A problem of uniformity of 
temperature within the instrument remains. We observed differences of up to 2oC 
in the same plate (manuscript in preparation). This suggests that for this type of 
experiments fluorometer should be equipped with more adequate temperature 
control. Currently samples are heated using air, which is typically known to be an 
insulator, if a more efficient conductor is used e.g. aluminium, the incubation time 
can be shortened to 5 min (manuscript in preparation). Which is more or less the 
same time that it takes to prepare the machine prior to the measurement, making 
the pre-heating step redundant.  
 
Recommendations 
Taking into account our current knowledge it stands to reason to perform a similar 
study as35 to determine how the suggested improvements to the CAT hold up in 
"real life" conditions. An improved inter-laboratory variability could expedite the 
clinical implementation of this versatile method.  
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Abstract 
 
Background Calibrated automated thrombography (CAT) is a global haemostasis 
assay and its outcome correlates well with bleeding and thrombosis risk. The assay 
itself has been proven to be highly sensitive for temperature, making temperature 
control of the experiment a necessary precondition for reproducible results. 
Temperature fluctuations throughout the experiment as well as between the wells 
in the plate have been shown to add to the variation in the results. 
 
Object ives In this study we aim to identify and where possible quantify the 
influence of temperature on thrombin generation (TG). Moreover, by comparing 
the difference in response between defibrinated normal pooled plasma (NPP) and 
regular NPP we aim to further elucidate whether the control mechanisms of 
thrombin formation are diffusion limited. 
 
Methods TG was measured at a range over temperatures from 30.5°C until 
38.5°C with 2°C intervals in NPP and defibrinated NPP. The TG parameters where 
calculated using the new insights presented in chapter 6. Prothrombin conversion 
and thrombin inactivation were assessed.  
 
Results  The TG parameters in NPP plasma where decreased at increasing 
temperature -3.2%/°C for the peak and -4.4%/°C for the ETP. Defibrinated plasma 
showed no temperature response for the peak and a -1.4%/°C decrease for the 
ETP. The calibration reaction increased with temperature by 3.8%/°C.  
No anomalies have been observed as a result of the lower substrate concentration. 
 
Conclusions TG parameters are decreased at increasing temperatures as a result 
of the difference in response of the pro- and anticoagulant processes of TG. 
Calibration of the TG increased the response to temperature changes in the TG 
parameters peak and ETP as a result of the opposite response to temperature 
between TG and calibrator.  
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Introduction 
 
Coagulation assays, the Calibrated Automated Thrombogram (CAT) as described by 
Hemker1 being no exception, try to mimic the human physiological conditions as 
closely as possible. We all understand that concessions have to be made, because 
we cannot (as yet) represent the full physiology of the human body in in vitro 
coagulation tests. However, the one physiological aspect that most of the test 
really stringently adhere to is the representation of the human core body 
temperature, which is generally excepted to be around 37°C with a healthy state 
being considered to be between 36,1°C and 37,2°C2.  
 
Coagulation is a highly complex mechanism that can easily be influenced by many 
factors one of these being temperature3,4. As a consequence, perfect 
thermostability is a condition sine qua non for reproducible measurement of 
thrombin generation (TG). It is therefore almost intuitively that we perform the 
test at 37°C. Unfortunately, as is shown in chapter 4, temperature also happens to 
be one of the sources of error of the test results of TG and therewith one of 
limiting factors of comparison of results between laboratories.  
 
The control of temperature in any device is often taken for granted and is generally 
considered to be the responsibility of the manufacturer. For the CAT it has been 
shown that both the instability of temperature throughout the 96 well plate5 as 
well as the temperature throughout the thrombin generation (TG) experiment3 
influence the outcome of the TG experiment. It is not the purpose of this chapter 
to further elaborate on the technicalities of temperature control, but since they 
are important to understand, they are briefly presented in an appendix to this 
chapter, therewith accompanied by a brief description of an amelioration for the 
CAT to improve temperature stability and control.  
 
TG is the result of prothrombin conversion and thrombin inactivation. If both 
processes would have approximately the same temperature coefficient, TG would 
be largely temperature independent and temperature control requirements would 
be easily met. Previously it has been shown, however, that lowering the 
temperature increases thrombin generation4. The assumption was that 
prothrombin conversion in the presence of fibrin is diffusion limited and therefore 
much less sensitive to lowering of temperature than thrombin inactivation4, which, 
like most (bio)chemical reactions will decrease its velocity (in a very rough 
approximation) by a factor two for every 10°C drop in temperature. Oddly enough, 
this observation is not supported by the clinic where hypothermia (<32°C) in 
trauma patients, is associated with an inadvertent bleeding risk6. 
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In the CAT method thrombin concentrations are calculated by comparing the 
fluorescence in the well where thrombin generates to that of the fluorescence that 
is generated in the calibrator well, where a known amount of α2macroglobulin-
thrombin (α2m-T) complex converts the same substrate under the same 
experimental conditions (3). A difference in the temperature between the 
calibrator and TG well would therefore lead to either an over or underestimation 
of the thrombin concentration. 
 
In order to investigate the extend of the influence of temperature disturbances on 
thrombin generation, we took a more fundamental approach by performing TG 
experiments at different temperatures. These experiments give us a good 
understanding of how the enzymatic reactions of the blood coagulation system 
respond to changes in temperature. And allow us to extrapolated and speculate on 
the influence of the more stochastic temperature fluctuations during the TG 
experiment. 
 
Material  and methods 
 
TG was measured in normal pooled platelet poor plasma (PPP) at 5 pM tissue 
factor (TF). A bespoke temperature controller was built into the fluorometer. It 
consists of a PID controller that steers a resistive heater attached to an aluminium 
mould. The aluminium decreases the overall temperature variation throughout the 
96 wells plate to < 0.1°C. The appendix to this chapter can be consulted for further 
information on the technical details behind the construction of the temperature 
controller. 
 
F luorescence based measurement of  thrombin act iv ity  
The development of fluorescence intensity from 7-Amino-4-methylcoumarin 
(AMC) was measured in a 96-well plate fluorometer (Ascent reader, 
Thermolabsystems OY, Helsinki Finland) equipped with a 390/460 filter set 
(excitation/emission) and a dispenser. Immulon 2HB, flat-bottom 96-well plates 
(Dynex) are used. six readings are done per minute and experiments have been 
carried out in quadruplicate unless otherwise indicated. Per temperature two 
separate runs of experiments have been performed. 
 
To each well, 80 μL normal pooled plasma is added. Wells in which TG is measured 
receive 20 μL of buffer I, containing 30 or 600 pM of recombinant tissue factor (TF) 
and 24 μM phospholipid preparation. Wells in which constant thrombin-like 
activity is measured receive 20 μL of the α2M-thrombin (α2M-T) solution which 
has a thrombin-like activity of 600 nM, resulting in a final concentration of 100 nM 
thrombin like activity in the well. Thrombin generation (TG) was initiated by the 
addition of 20 μl of ZGGR-AMC (150 μM) and CaCl2 (16.6 mM). 
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The dispenser of the fluorometer is flushed with mili q water, emptied and then 
flushed with a prewarmed solution of the substrate and calcium in buffer II 
(referred to as FluCa) as stated in the Thrombinoscope manual. The “FluCa trigger” 
solution, a mixture of fluorogenic substrate and CaCl2 is prepared as follows. To 
1782 μL of buffer B, at 37°C, 200 μL of 1 M CaCl2 is added, then 18 μL of a DMSO 
solution of 50 mM ZGGR-AMC is squirted in and immediately vigorously mixed on a 
vortex. The pre-heating temperatures of the dispensing liquids have been adjusted 
to the measurement temperatures accordingly. At the start of the experiment, the 
instrument dispenses 20 μL of the substrate/calcium mixture to all the wells, 
registers this as zero time, shakes them for 10 s and starts reading. 
 
Reagents 
Innovin recombinant human Tissue Factor (rTF) was used at final concentrations of 
5pM and 100pM (Dade-Behring, Marburg, Germany). The calibrator (α2m-T) was 
prepared as previously described by Hemker et al.7. Procoagulant phospholipids 
(PL), containing 60% dioleoyl PC, 20% dioleoyl PS and 20% dioleoyl PE, were 
prepared as described by8. ZGGR-AMC was purchased at Bachem (Basel, 
Switzerland) and dissolved in DMSO to a stock concentration of 50 mM.  
 
Buffers  
Buffer I used in the preparation of dilutions of the reagents: 20 mM Hepes, 140 
mM NaCl, 0.02% NaN3 and 5 mg/mL BSA at pH 7.35.  
Buffer II Used for the solution of the fluorogenic substrate: 20 mM Hepes, 0.02 % 
NaN3 and 60 mg/mL BSA at pH 7.35. The buffers are filtered using a corning filter 
system 250 mL with 0.2 µm PES membrane and stored at -20°C.  
 
P lasma preparation 
Blood was obtained through antecubital venepuncture (1 volume trisodium citrate 
0.13 M to 9 volumes blood) in a 10 ml vacutainer tube (BD, San Jose CA, USA) from 
apparently healthy volunteers after agreement to informed consent in 
concordance with the declaration of Helsinki. The blood was centrifuged twice at 
2,821g at room temperature for 10 minutes (min). Platelet-poor plasma was 
collected, and a pool (NP) was prepared and stored in 1 ml containers at –80°C. 
 
Defibr ination of  normal pool  p lasma 
Plasma was defibrinated using 1 U/ml ancrod (NIBSC, South Mimms, UK). The dried 
ancrod powder was dissolved in milli q water so that 17 μl could be added to 983 
μl of citrated normal pool plasma to get the 1 U/ml final concentration. A clot was 
allowed to form during a 10 min incubation at 37°C, and a subsequent 10 min 
incubation on ice. The fibrin clot was removed by winding it on a plastic spatula. 
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Data handl ing 
The raw data of optical density or fluorescence measurements of thrombin activity 
were exported to Excel (Microsoft Excel 2003) and corrected for substrate 
consumption and non-linearity of fluorescence with the concentration of the 
fluorophore by the method further described in chapter 6 of this book. The 
thrombin decay constants and the subsequent curves for prothrombin conversion 
and thrombin decay where determined according to the method of Kremers9.  
The TG parameters used to represent the temperature effects are limited to the 
Calibrator level, the PEAK and the ETP. The Lagtime and Time to Peak are not 
included as they give an incomplete overview of the action of thrombin over time 
and are therefore considered to be less representative to elucidate the full scope 
of the influence of temperature on TG. 
 
Results  
 
Temperature dependencies  
In the first column of tables 1 and 2 the temperature dependency of the 
calibration reaction. both in NPP (table 1) and in defibrinated NPP (table 2), are 
shown. The average increase in calibrator activity is around 4% per 1°C, with little 
more increase in the calibrator from 36.5°C to 38.5°C. This differs from the 
temperature dependencies of the TG reactions that are shown in columns 2-5 of 
tables 1 and 2, moreover there are also distinctive differences between the NPP 
and the defibrinated NPP experiments 
 
The TG activity is represented here by the PEAK and the ETP values, in the NPP 
both values decrease with an increase of temperature, table 1. columns 2 and 3. 
The PEAK value decreases with an average of 3.2% per °C and the ETP with 4.4% 
per °C. No stagnation of the decrease of Peak and ETP values is observed from 36.5 
to 38.5°C. The decrease of PEAK and ETP values is aggravated when the data are 
multiplied with their respective calibration factors, table 1 columns 4 and 5. This 
can be explained by the opposing temperature trends between the TG and the 
calibration experiments, this causes the lowest temperatures to be corrected less 
and the highest more.  
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Table 1: Temperature dependence of the TG experiment from 30.5°C until 38.5°C 
measured in NPP. 
 
Temp 
°C 
Cal ibrator 
s lope 
dF/dt  Thrombin  
Peak Max 
FU 
ETP  
FU*min 
Peak  
nmol/L 
ETP  
nmol .min/L 
Average Average Average Average Average 
30.5 145±1.9 310±2.5 1568±12.5 224±1.8 1140±9.1 
32.5 163±6.4 297±5.6 1409±26.7 187±3.5 892±16.9 
34.5 176±3.7 277±3.4 1301±16.1 163±2.1 772±9.5 
36.5 185±2.6 268±6.5 1175±28.5 145±3.5 639±15.5 
38.5 186±2.7 225±4.4 1039±20.2 120±2.4 552±10.7 
(%/°C) +3.8 -3.2 -4.4 -4.6 -5.6 
 
Table 2: Temperature dependence of the TG experiment from 30.5°C until 38.5°C 
measured in defibrinated NPP. 
 
Temp 
°C 
Cal ibrator dF/dt FU Thrombin  
Slope 
Peak Max 
FU 
ETP  
FU.min 
Peak  
nmol/L 
ETP 
nmol.min/L 
Average Average Average Average Average 
30.5 154±2.3 175±2.7 730±11.1 125±1.9 589±8.9 
32.5 167±7.1 167±4.7 683±19.3 106±3.0 495±14.0 
34.5 190±3.1 169±2.9 680±11.5 97±1.6 448±7.6 
36.5 200±2.1 171±2.5 678±9.9 91±1.3 399±5.8 
38.5 205±1.9 163±2.8 652±11.3 83±1.4 337±5.8 
(%/°C) +3.8 +0.001 -1.4 -2.8 -4.5 
 
In defibrinated NPP the effect of a diminishing Peak and ETP is much less 
pronounced with no decrease of the Peak and a 1.4% per 1°C decrease of the ETP, 
table 2 columns 2 and 3. Again this effect is amplified by the calibrator table 2 
columns 4 and 5, where the multiplication with the calibration factor enhances the 
effect to 2.8 and 4.5 % per 1°C decrease for the Peak and ETP respectively. The 
Lag-time in both instances, NPP and defibrinated NPP, decreases with increasing 
temperature from 1.16 min at 30.5°C to 0.83 min at 38.5°C, suggesting a more 
procoagulant state at higher temperatures. 
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An approximation of the decay constants for NPP and defibrinated NPP can be 
found in table 3 an increase in the constants can be observed with increasing 
temperature. 
 
 Table 3. Approximated decay constants for TG experiments at a range of temperatures 
 
Temperature Decay constant def ibr inated 
NPP 
Decay constant 
NPP 
30.5 -0.71 -0.42 
32.5 -0.85 -0.49 
34.5 -0.90 -0.56 
36.5 -1.04 -0.63 
38.5 -1.04 -0.72 
 
Figure 1 illustrates the prothrombin conversion curves that have been obtained 
using the method by Kremers et al.9 and the decay constants from table 3. It shows 
an overall slight increase in prothrombin conversion with time. In defibrinated 
NPP, figure 2, the increase in prothrombin conversion is more pronounced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: approximation of prothrombin conversion in NPP measured at 5pM TF. 
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Figure 2: approximation of prothrombin conversion in NPP measured at 5pM TF. 
 
Substrate concentrat ion 
The maximum level of fluorescence that was attained in these experiments with a 
substrate concentration of 150 μM was 3200 FU. The highest level of fluorescence 
over the functional part of the TG curve was measured at 2000 FU for the 100 pM 
TF concentration at 28.5°C. 
 
Discussion 
 
Humans are homeothermic (warm blooded) species, they generally have a core 
body temperature of 37°C. Several mechanisms of heating and cooling are applied 
to sustain this steady state thermal equilibrium. These mechanisms combined with 
the irregular geometry of the human body, lead to a complicated three-
dimensional temperature distribution. This causes a temperature gradient that is 
not just longitudinal but also axial. Moreover, this gradient is greatly influenced by 
the outside temperature. To assume that 37°C is therefore the most 
representative temperature to measure coagulation is by itself up for debate.  
 
Heat loss is, in part, regulated through conduction in the peripheral blood flow. 
The large vessels that lie deeper in the extremities are in parallel with one another. 
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This allows the warmer outward flowing arterial blood to give off heat to the 
inward flowing venous blood. This so-called counter-current principle causes a 
steeper axial temperature gradient. When thrombosis, that is often found in veins 
of the lower legs, is considered, it just as likely as not that it occurs under lower 
temperatures <35°C then at 37°C. And if the temperature was lower, a different 
dynamic of the coagulation system led to its formation. 
 
Moving beyond the temperature differences it can be further narrowed down to 
the site of an injury where a temperature gradient can very well be expected 
between the underlying tissue and the ruptured skin and vessels that are exposed 
to the air. Heat loss of the blood and tissue as they are exposed to air is very likely 
to be expected at the site where the plug has to be formed to halt bleeding. 
 
Our results show that thrombin generation increases considerably when the 
temperature drops. In the 30.5-38.5°C interval the ETP increases by nearly 5.6% 
per degree and the peak by 4.6%. Thereby providing a possibly explanation for the 
degree of variation that can be a result of a temperature gradient within the plate 
and/or throughout the experiment.  
 
The increase of thrombin generation with decreasing temperature is much more 
apparent in the presence of a fibrin web, this contradicts the previously made 
assumption that in the presence of a fibrin web prothrombin conversion is 
diffusion limited and therefore less temperature dependent than thrombin 
inactivation, which is a bi-molecular reaction in free solution4. However, the 
prothrombin conversion curves and decay constants illustrate that both 
prothrombin conversion and thrombin decay increase with increasing 
temperature. The overall result of a decrease in TG with increasing temperature 
can therefore only be explained by the fact that the procoagulant reactions are 
influenced less by temperature than the decay reactions. This again hints to the 
possibility of diffusion limited reaction rates in thrombin formation but these 
results are however not conclusive enough to either confirm or reject the 
previously posed hypothesis in the work by Hemker et al.4. 
 
The contradictory results of the TG with lowering temperatures are a good 
example of the surplus value of measuring beyond the formation of a clot. Whilst 
clot formation i.e. the clotting time are delayed with decreasing temperature, 
overall TG as represented by the PEAK and the ETP are increased, indicating a 
more prothrombotic phenotype. Interestingly it is believed that bleeding is a result 
of hypothermia in trauma patients, the idea that this bleeding is amongst other 
things a result of delayed reaction rates of the clotting enzymes is supported by 
clotting times 6 but now contradicted by TG results. The result of the differences 
between these reactions in NPP is that the overall lower amount of thrombin is 
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able to cleave more substrate over a longer time at lower temperatures where it is 
cleared less rapidly relative to its formation. 
 
The differences in the influence of temperature between the TG- and the 
calibrator well and deviations from the standard (37°C) temperature will influence 
the results of a CAT experiment. A multiplication by a calibration standard that was 
also under the influence of the same temperature fluctuation can therefore 
aggravate the variation that is observed in either of the two parameters alone.  
 
Being the first series of experiments to be performed with a 150 μM substrate 
concentration, albeit out of necessity, no adverse consequences where observed 
throughout the experiment. Moreover, the maximum fluorescence of the 
functional part of the TG curve never surpassed more than 60% of the maximum 
fluorescence attainable for this substrate concentration in any of the experiments. 
The defibrinated samples do reach the maximum fluorescence over the course of 
60 min that the experiment is run. However, this is due to the large contribution of 
α2M-T, that clears a larger portion of thrombin in the absence of fibrin, the 
relevant part of the TG curve has finished long before this value is reached. 
Therefore, the most important precondition for the calculation method that was 
used and that will be further elaborated upon in chapter 6 still seems to be 
fulfilled.  
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The global hemostatic assay that measures thrombin generation (TG) in plasma 
increasingly gained attention as a diagnostic tool in the field of thrombosis and 
hemostasis. The Calibrated Automated Thrombin Generation test (CAT-TG)1 has 
been used in research laboratories for over 15 years now. And has over this period 
of time been implemented in over a thousand research laboratories worldwide.  
Throughout the last decades considerable evidence has been published that the 
amount of thrombin activity measured with TG is an indicator of the risk of 
bleeding2–5 as well as venous thrombosis6–14. TG can be used to distinguish mild 
from severe bleeding phenotypes in hemophilia A patients with comparable factor 
VIII levels15. It also relates to the risk of arterial thrombosis, be it in a less 
straightforward manner16–18. It is a common denominator of the effect of all 
anticoagulants19–26 and, when it is measured in platelet rich plasma, it is inhibited 
by platelet inhibitors27,28. Therefore, it has a promising outlook for use as a clinical 
parameter. Nevertheless, its implementation in the clinical laboratory until this 
moment is very limited.  
 
One reason is that the CAT-TG is not a fully automated method like most other 
methods in the clinical routine laboratory. It still requires an amount of old-
fashioned laboratory labour. Apart from the fact that this is not in line with 
modern laboratory management, it also introduces the executor as a cause of 
inter-laboratory variability. Strict training of the technicians is a sine qua non for 
obtaining acceptable results (Prof. Y. Dargaud, personal communication). 
 
Another way to introduce TG in the clinic is by so called near patient testing or 
point of care (POC) testing29–31. In chapter 2 we described the development of a 
near patient, miniaturized device based upon a previously published method, 
developed in our laboratories, that allows the measurement of TG in whole-
blood32. Measurement in whole blood is necessary anyhow because obtaining 
plasma by centrifugation is hard to realise in a point of care situation. Anyhow, a 
full TG-curve requires about 15 minutes, which is long if an immediate answer is 
required as e.g. in emergency bleedings.  
 
To further decrease the turnover time an alternative calculation method is 
presented in which only the data until the peak of the TG are used. Although much 
information present in the total TG is thus discarded, it can be argued that both 
pro- and antithrombotic processes contribute to the peak value and the area 
under the TG curve up to the peak value. In how far this information is useful and 
sufficient remains to be determined for each individual pathological condition. One 
can imagine e.g. that it suffices as a quick estimate of the effects of vitamin K 
antagonists and heparin but that it will do worse for direct inhibitors of factor Xa, 
due to the blunted form of the TG-peak that such anticoagulants induce. 
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In chapter 2 we show that we have been successfully able to miniaturize the device 
to have a similar inter-assay variation as the original test. The fact that only one 
sample can be measured at any time excludes determination of the intra-assay 
variation. Also, the impossibility of a simultaneous control step will increase the 
chances of introducing errors. Nevertheless, a comparison of the results obtained 
with the adapted calculation method to the standard shows decent correlation 
coefficients 0.868, 0.998, 0.993 and 0.981 for the (peak)ETP, peak, lag-time and 
time-to-peak, respectively. The imperfect correlations are most likely due to the 
fact that the information from the decay phase of thrombin generation is 
discarded. 
 
Clinical validation of this test has been performed on a group of 33 patients that 
underwent cardiothoracic surgery, with the aim to check whether the test would 
predict the degree of blood loss. After division of the patients into two groups 
(severe and mild bleeders) based on the mean drainage volume, a statistically 
significant difference was found between the two groups for the peak-ETP and the 
peak. This does not proof that the test can be used for predictive purposes but it is 
indicative of a statistically significant association. In the designing of this 
experiment, we had to trade of between the desire to have a homogenous sample 
population and a large number of samples. We have chosen for the first and 
restricted the type of intervention to Coronary Artery Bypass Grafting (CABG). This 
caused the sample size to be small and leaves room for more extensive studies in 
the future.  
 
Simultaneously with the development of the near patient TG device, we wanted to 
make use of the miniaturised set-up to explore possibilities of alternative 
applications of TG. The zebrafish being a more and more used model, notably in 
fundamental studies on the relation between the genome and anatomy and 
physiology, we wanted to investigate whether this animal also could be used in 
experiments on coagulation physiology.  
 
In chapter 3 we show that by applying the miniaturised model to zebrafish we are 
able to generate TG curves with an acceptable inter-individual variation with a 
mean CV of 14%. Moreover, we were able to detect a dose-response effect of two 
anticoagulant drugs: Rivaroxaban (a direct FXa inhibitor) and Melagatran (a direct 
FIIa inhibitor). Despite an encouraging start, the lack of physiological similarity 
between zebrafish and humans has led us to decide not to continue this path any 
further at this moment. Nevertheless, we believe that being able to measure 
extremely small quantities of blood in such frail animals brings many opportunities 
for future animal studies. 
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After this brief animal excursion, we understood that the miniaturized version, that 
we derived from the whole blood-TG method was in its current form not the way 
to quick clinical application.  
We realized that one of the major drawbacks in the method remained the, 
relatively large, inter-laboratory variability and bad standardization criteria33–36 
which are only partly ameliorated by normalization33–35,37. Notably in the case of 
(extreme) hypo coagulability normalization is not able to reduce the inter-
laboratory variation. As the matter of fact normalization actually caused an 
increase in variation of some of the parameters33.  
 
We were in the lucky circumstance that, through the cooperation with a number 
of clinical labs, we could lay our hands on the raw fluorescence curves from a 
reproducibility study carried out in France. Analysis of these curves allowed us to 
gain insight into the reasons for the large interlaboratory variability (Chapter 4). 
The biggest contributor to the total error appeared to be the comparison between 
the TG-sample and the calibrator. We were able to assess the contribution of the 
calibrator to the total error by making use of the ratio between the ETP and the 
end-level of α2M-T. This can be done because the proportion, to which ETP is over- 
or under-estimated by the calibration procedure, is the same as the proportion to 
which the final level of α2M -T is under- or overestimated. 
 
By applying this correction, the inter-laboratory CV for the ETP could be reduced 
from 16,3% to 11,7%. A similar trend is observed for the thrombin peak in which 
the inter-laboratory CV is reduced from 17,4% to 11,9%. It thus appears that the 
calibration step, that has been designed as a tool for quantification and elimination 
of the known (inner filter, substrate consumption and plasma colour) and 
unknown measurement artefacts, in fact contributes significantly to the 
experimental error. This phenomenon can, hypothetically, be attributed to two 
reasons: The first is that in any procedure in which the data from two observations 
(calibrator and TG-curve) are combined, the experimental error in the outcome 
sums-up. The second being that the calculations used to combine the outcomes 
introduce systematic errors.  
As a second major source of error we could identify the inconsistency of 
temperature, in particular as a result of inadequate pre-heating of the sample. We 
therefore had a closer look into both temperature control and calculation 
methods. In chapter 4 we re-introduce the “diagnostic plot” as a tool to determine 
temperature stability at the start of the experiment. The diagnostic plot is a plot of 
the first derivative of the fluorescence curve against the value of the fluorescence 
itself 38,39. 
 
In a calibrator experiment performed at constant temperature, dF/dt is at its 
maximum at zero time because both the substrate concentration is highest and 
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the inner filter effect is still absent. An increase of dF/dt at the start of the 
experiment can therefore only relate to an increase of temperature. The 
characteristic “hockey stick” shape of the first derivative of the calibrator curve can 
only indicate a rise in temperature at the start of the experiment as there is no 
other explanation for the increase in reaction velocity. This error is mainly due to 
the operator that has not pre-heated the sample to the exact value of that in the 
fluorometer. Design changes to the software that enforce a fixed pre-heating time 
as well as creating operator awareness of the importance of temperature could 
partly improve the situation, be it that the time required to attain the right 
temperature is longer than ten minutes and that evaporation of the sample begins 
to play a role then.  
 
After having seen the important role of temperature in the CAT-TG and not having 
been able to find any conclusive literature on the topic of temperature and TG, we 
decided to investigate the influence of temperature further in systematic matter, 
not just as a source of error. In chapter 5 the results of a series of TG 
measurements that have been performed over a range of temperatures (30.5°C – 
38.5°C) are presented. Since temperature control and stability of the device 
appeared not to be up to the required standards, it was decided that a technical 
amelioration imposed itself. On purpose the technical details are not discussed in 
chapter 5 but in an appendix, as they are of a very different nature than the rest of 
the chapter. It is nevertheless vital to illustrate the intricacies of temperature 
control to fully understand why the current method is not sufficient. 
 
The influence of temperature on TG was measured in normal pooled plasma (NPP) 
and in defibrinated NPP, in order to find an answer to the hypothesis weather or 
not TG is diffusion controlled. The assumption was that prothrombin conversion in 
the presence of fibrin is diffusion limited and therefore much less sensitive to 
lowering of temperature than thrombin inactivation 40. In reality the opposite 
seems to be true with the defibrinated plasma showing much less of response to 
temperature changes, +0.001 %/°C for the peak values and -1.4 %/°C for the 
endogenous thrombin potential (ETP). NPP plasma on the other hand is more 
influenced by temperature with a decrease of -3.2%/°C for the peak and 4.4%/°C 
for the ETP. 
 
The observation that TG is decreasing with increasing temperature is counter 
intuitive as most (bio)chemical reactions increase with temperature. TG however 
consists of both pro- and anticoagulant process and as the data in chapter 5 
illustrate the procoagulant reactions are less influenced by temperature as 
compared to the anticoagulant reactions. If both these processes would be 
influenced in the same way by temperature, TG would be temperature insensitive. 
However, the combination of a lower overall prothrombin conversion with an even 
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more decreased activity of the antithrombins explain a higher apparent thrombin 
generation. This difference in response between pro- and anticoagulant responses 
can potentially be explained by the original hypothesis of diffusion-controlled 
mechanisms of thrombin formation. Unfortunately, experimental constraints in 
determining accurate decay constants and the lack of sensitivity of the 
measurement do not allow to either support or falsify this hypothesis.  
An important practical point is the influence of temperature on the calibration 
experiment, that differs markedly from that on thrombin generation. The velocity 
of substrate conversion by the calibrator increases with increasing temperature 
and unlike thrombin generation, that decreases. This increases the temperature 
dependency of the thrombin generation curve that results from the comparison 
with the calibrator.  
 
Inspection of a calibration curve immediately shows that it is far from being a 
straight line. Because of this non-linearity the calibration factor that converts the 
observed reaction velocity into an enzyme concentration changes with the level of 
fluorescence. Two mechanisms are thought to cause this phenomenon: Firstly, the 
inner filter effect (IFE) which makes that the fluorescence intensity decreases 
proportionally to the increasing concentration of fluorescent product. Secondly, 
substrate consumption (SC), which causes the reaction velocity to decrease 
proportionally with enzyme concentration as the reaction proceeds. In the CAT-TG 
an algorithm is used that compares the fluorescence curve from the calibrator well 
with the TG well and corrects for IFE and SC (see39). This algorithm is not based on 
insight in the mechanisms (IFE and SC) and therefore could be a source of error. In 
chapter 6 these phenomena that cause the non-linearity of the calibration reaction 
of TG are assessed and a calculation method is presented based on the insight into 
the mechanisms. 
 
The relation between the measured fluorescence (Fexp) and the concentration of 
the fluorophore (C) is known to be: F = 𝐴𝐶𝑒!!"  with F=fluorescence, 
C=concentration and A and b constants. We found that within the range of 
fluorescence that we encounter in our experiments this formula can be replaced 
by 𝐹!"# = 𝐹!"#(1 − 𝑒!!"). We show that the latter formula, in contrast to the 
first allows to develop a simple expression for the correction of the inner filter 
effect: 𝐹!"#$% = −𝐹!"#  𝑙𝑛 1−𝐹!"#/𝐹!"#  (Chapter 6). This formula is generally 
applicable and is based on the optics of the inner filter effect.  
 
In any fluorometer of the type used for the CAT-TG, this formula can be used after 
normalization of the fluorescence intensity at 300 µM AMC to 1000 AU and using 
2090 as the value of 𝐹!"# or, alternatively, using 2.09 times the fluorescence 
intensity at 300 µM AMC for 𝐹!"#. This operation will work as long as all other 
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variables of the lambert-beer equation (𝐴 = 𝑙𝑜𝑔!" !!! =  𝜀. 𝐼. 𝑐) stay the same. 
Mind that the intensity of fluorescence at 300 µM is not a constant for a given 
fluorometer but changes with the intensity of the excitation light source, which 
diminishes with time. The fluorescence intensity at 300 µM AMC should therefore 
be regularly controlled. 
The experiments presented in chapter 6 show that the conversion of substrate by 
α2M-T can be described by the classical Michaelis-Menten hyperbola 
!"!" =𝐸. 𝑘!"# . 𝑆/(𝐾𝑚 + 𝑆), so that we can calculate the relation between reaction 
velocity and enzyme concentration as 𝐸 = (!"!")(𝐾𝑚 + 𝑆)/(𝑘!"# . 𝑆), after the IFE 
has been corrected for with the abovementioned formula. This relation between 
reaction velocity and enzyme concentration is independent of a calibrator curve, 
the calculation only requires that the kinetic constants Km and kcat are known. 
 
The variation in the optical density of the plasma due to the difference in colour of 
individual plasmas can be as large as 10%, ignoring the plasma colour could 
introduce considerable experimental variation. Plasma colour being directly 
related to the optical density can however easily be corrected for with a simple 
multiplication factor. 
 
The fluorogenic substrate that is used in TG is only soluble in a buffer containing 
high quantities of Bovine Serum Albumin this implies that the substrate binds to 
albumin. Given the fact that albumin is the most abundant plasma protein made us 
question how changes in albumin level could influence a TG- experiment. We 
therefore investigated the influence of albumin concentrations on the conversion 
of ZGGR-AMC by thrombin and by α2M-T in chapter 7. This involves measurement 
of the initial rates of substrate conversion in buffer with different concentrations 
of albumin. Classical enzyme kinetics requires measurements of initial rates, i.e. 
measuring in a time frame where substrate consumption is negligible. This 
however is precisely the time frame in which the measurement in a fluorometer of 
the type we used is instable. We therefore measured over the time frame in which 
the product curve is parabolic. A parabolic progress curve implies a linear relation 
between reaction velocity and substrate concentration. This is to be expected in 
the beginning of the reaction where the change of S in the numerator of the 
Michaelis-Menten equation (𝐸. 𝑘!"# . 𝑆) does count whereas in the denominator (𝐾𝑚 + 𝑆) it is still negligible because 𝐾𝑚 ≫ 𝑆 The initial rate therefore can be 
calculated as the linear component in a parabola fitted to the first part of the 
fluorescence trace. This principle is applicable to the measurement of initial rates 
of calibrator curves in plasma as well. 
 
General  Discussion and Conclusions 
	 155	
We found that albumin has hardly an influence on the kinetic constants of 
thrombin but a large influence of the Km of α2M-T. This we explained by assuming 
that the substrate binds reversibly to albumin but that thrombin is capable of 
splitting the bound substrate whereas α2M-T is not. 
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Substrate concentrat ion 
In chapter 8 an assessment of the influence of the fluorogenic ZGGR-AMC 
substrate on the TG experiment was investigated in a concentration dependent 
manner. The presence of the substrate causes a fraction of the thrombin to be 
substrate bound to its active centre. Therefore, less thrombin is available to 
interact with its inhibitors antithrombin (AT) and α2Macroglobulin (α2M). Indeed, 
substrate was found to increase TG values because of this competition. Splitting 
the TG curve in a prothrombin conversion- and a decay-curve41 showed that the 
main effect of the substrate is on the attenuation of TG by decreasing its half-life 
time. Naturally, occupation of the active center of thrombin by substrate not only 
slows down decay but also inhibits positive feedback effects like those on factors 
V, VIII XI and negative effects after binding of thrombin to thrombomodulin. This, 
theoretically, calls for using minimal substrate concentrations. The original choice 
for the concentration of the thrombin substrate was dictated more by solubility 
than any other consideration (chapter 7).  
 
In chapter 4 we lowered the substrate concentration of the experiments to 150 
µM and found no adverse effects on the thrombin generation curves. At this 
concentration no considerable effect of substrate depletion was observed as the 
end level fluorescence of the TG experiment was about 65% of the maximum 
fluorescence, like in experiments at higher substrate concentrations. It thus 
appears that substrate consumption is roughly proportional to the inhibition of 
thrombin decay by the substrate. 
 
Now the question poses itself whether we can suggest amelioration of current 
practice of TG-measurement in the light of our results, either by adaptations that 
relate to calibration, to the fluorogenic substrate, to the calculation method and to 
technical ameliorations. 
 
Cal ibrat ion 
Calibration is currently a necessity to be able to quantify the amount of thrombin 
generated and to correct for the specific colour of the plasma as well as for the 
inner filter effect and substrate consumption. The calibration experiment is run in 
parallel in a separate experimental well. Even at the highest level of scrutiny an 
increase of experimental error must be introduced by comparison of two 
experiments and the calculations that this involves. The most adequate solution for 
this would be to abolish the need for an "external" calibration experiment and 
internalize it. It has been suggested by Hemker (A self-calibrated thrombin 
generation assay. European patent application P6066184EP) that it is possible to 
use an “internal” ratio for the calibration. When a small fixed amount of product is 
added to the reaction mixture before the start of the TG reaction, and when the 
inner filter effect is compensated for so that fluorescence is proportional to 
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product concentration, then the progress of the reaction can be expressed as the 
ratio of the level of fluorescence to the initial level. 𝑟!"# = ((𝐹!"#/𝐹!) − 1). This 
already compensates for effects of the colour of plasma etc. Also, this allows to 
express the progress of the reaction in terms of the fraction of substrate 
consumed. From the present work we know that simple Michaelis-Menten kinetics 
apply, so it must be possible to calculate, at each level of substrate consumption, 
the amount of enzyme (thrombin) that causes the measured reaction velocity. 
 
The f luorogenic  substrate.  
The substrate has a pronounced effect on the development of the TG curve as the 
substrate competes for thrombin with the natural substrates that are present in 
the plasma. We have shown the main effects to be in the thrombin decay phase 
and to a lesser extend in the thrombin formation phase. Moreover, we have also 
shown that it is possible to correct for the competitive effect of the substrate. 
Ideally a substrate with very high Km should be used of which only a small fraction 
is consumed. In that case Km+S remains practically constant during the experiment 
and the reaction velocity is simply proportional to enzyme concentration and 
substrate concentration, which, in combination with the ratio method mentioned 
above would allow simple direct determination of the TG-curve. 
Substrates that are not split by the α2M-T complex have many advantages: less 
substrate will be consumed and the inner filter effect would be less important, as 
the overall fluorescent trace would remain relatively low. The calculation step 
required to eliminate the contribution of the α2M-T complex to the total 
amidolytic activity would become superfluous, so that it would be easier to 
determine the end of the TG experiment. 
 
In chapter 4 we highlight the main bottleneck of the α2M-T macroglobulin 
correction. In the experimental procedure, the course of total amidolytic activity 
fa(t) is found, consisting of free thrombin fg(t) and α2M-T. Because the velocity of 
formation of α2M-T in the pseudo first order reaction α2M + T → α2M-T is 
proportional to the concentration of free thrombin, the total amount of α2M-T 
formed is k times the integral of the thrombin-time curve. It is therefore seemingly 
easy to estimate the contribution of α2M-T to the total amidolytic activity. In 
practice however there is one glitch, because in order to be able to determine this 
constant a point in time has to be found where all free thrombin has disappeared. 
The key element in this process is that if k is underestimated, part of the activity of 
α2M-T is attributed to free thrombin and contributes to the ETP, whereas when k is 
overestimated part of the free thrombin is attributed to α2M-T. With use of the 
current substrate no satisfiable solution to end level determination has been found 
yet.  
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Besides the perfect substrate, which might be challenging to synthesise, gains can 
already be made by altering the current substrate concentration. Lowering to 
substrate concentration to e.g. 150 µM would not only reduce the inner filter 
effect but also benefits the TG experiment as there is less competition between 
the substrate and the serpins inhibiting TG.  
 
Technical  ameliorat ions to the device.  
An obvious improvement would be the level of accuracy of the temperature 
control within the TG device. Whatever the temperature of the measurement will 
be, there is still a need for accurate temperature control as measuring at room 
temperature is not an option. The inter-laboratory temperature differences as well 
as seasonal variations in the laboratory would then prove to be new sources of 
error. A second adaptation would be the excitation light source, the stability of the 
intensity of the light source is of vital importance especially when a standard 
correction factor for the inner filter effect is to be used. Only LED’s fulfil these 
requirements because they are stable throughout their lifetime. Both tungsten-
halogen and mercury/xenon arc lamps, the only reasonable alternatives, show a 
decay with time and they have considerable pre-heating times during which their 
output intensity is highly variable.  
 
In  short: The CAT-TG test that is the most used at the moment and, in a slightly 
modified form, a candidate for clinical application is essentially the same as that 
proposed by Hemker et al. almost twenty years ago. Hundreds of articles have 
shown its potential use in clinical and fundamental research and promise it to be 
useful in patient care. In this thesis we show that fundamental ameliorations of the 
original design are possible and desirable.  
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